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Brucellosis is a disease affecting a wide range of domesticated animals and wildlife as well 
as humans. The disease remains a major zoonotic problem in many regions including the 
Middle East. In Iraq, where brucellosis is endemic, the disease is a major economic and 
production limiting disease for livestock owners and the community. Impacts on production 
arise from reduced milk production, abortions, decreased reproduction rate and premature 
births. The aim of this project was to investigate the seroprevalence, risk factors and 
economic impact of brucellosis in sheep and goats in the Kurdistan Region. Also a 
retrospective study of human brucellosis in Iraq was conducted to describe the historical 
distribution of the disease and its impact on the population. 
 
Fifty one (39 sheep and 12 goats) of 1,050 sera samples were positive on both an RBT and 
ELISA (overall seroprevalence of 4.9%; 95%CI 3.6 - 6.3). Although there were no significant 
differences between groups, the highest seroprevalences were reported in sheep, male 
animals (sheep and goats) and animals (sheep and goats) older than 6 months compared with 
goats, female animals and animals younger than 6 months of age, respectively. A 
multivariable logistic-regression analysis was undertaken to identify risk factors for infection 
in flocks. This analysis indicated that farmers who introduced (purchased) new sheep (OR: 
4.24, 95%CI 1.0, 17.3) and who introduced (purchased) new goats in the 12 months 
preceding the survey (OR: 15.2, 95%CI 3.0 - 76.36) were significantly more likely to have 
seropositive flocks. In contrast, flocks that used water sourced from a well (OR: 0.27, 95%CI 
0.09 - 0.84) and had goats vaccinated against brucellosis in the 12 month period preceding 
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the survey (OR: 0.31, 95%CI 0.12 - 0.75) were significantly less likely to have seropositive 
flocks. 
 
Based on the data available, the total economic impact of brucellosis in sheep and goats in 
2015 was estimated to be US$6.14 million (95%CI 4.48 - $7.96 million) ($2.56 per adult 
female) in the Kurdistan Region. By adopting a mass vaccination control program for 10 
years the economic losses arising from abortions and decreasing milk production were 
estimated to decrease to US$1.83 million (95%CI 1.33 - $2.39 million) (US$0.76 per adult 
female). The median cost of the mass vaccination program over the ten-year period was 
estimated at US$7.18 million (95%CI 7.11 - $7.25 million) and the total median benefit in 
present day dollars was estimated at US$18.42 million (95%CI 13.43 - $23.83 million). The 
abortion rate had the largest effect on the outcome (regression coefficient = 0.74) followed 
by the prevalence of the disease (0.63). 
 
Based on the official records, the average annual incidence of brucellosis in Iraq, for the 
period from 1988 to 2002 was 41.88 cases per 100,000 people. There were significant 
differences between years (overall P value < 0.0001) with the highest annual incidence of 
88.2 cases per 100,000 people occurring in 1995. The average annual incidence over this 
five-year period (2004 to 2008) was 54.11 per 100,000 people in Kurdistan which was 
significantly higher than the 17.82 per 100,000 people in the rest of Iraq (RR 3.0; 95%CI 
1.76 - 5.11). The average annual incidence of brucellosis per 100,000 people for the period 
2009 to 2014 in four different provinces of Kurdistan was 36.74. The median cost per patient 
diagnosed with brucellosis was estimated to be US$321.78 (95%CI 259.53 to $388.72) in 
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the Iraqi Kurdistan region in 2014. The median annual DALYs due to the disease was 
estimated to be 27.17 (95%CI 15.81 - 42.65) per 100,000 people per year. 
 
It is recommended that to effectively control brucellosis in small ruminants in the Iraq 
Kurdistan region, an integrated approach should be implemented including adopting risk-
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Brucellosis, also known as Malta fever, Mediterranean fever and undulant fever (Corbel et 
al. 2006), is a zoonotic disease which can infect a wide range of domestic and non-
domesticated animals (Pappas et al. 2006). It is recognised as a significant problem 
throughout the world, particularly in the Mediterranean Region, north and east Africa, the 
Middle East, South and central Asia, India, and central and South America and is considered 
one of the most important zoonotic diseases internationally (Arroyo Carrera et al. 2006, 
Pappas et al. 2006). Despite the fact that many countries have implemented control 
programmes against the disease, it still remains a major health problem for humans and a 
disease of economic importance in livestock (Seleem 2010), even though the causative agent 
was first recognised by David Bruce over 130 years ago (Bruce 1887). 
  
Infected animals, in particular cattle, sheep, goats and pigs, are the main source of brucellosis 
for humans. According to Deqiu et al. (2002) there are approximately 1.8 billion sheep in 50 
countries in regions where B. melitensis is endemic, 1.3 billion cattle in 101 countries with 
endemic regions for B. abortus and 0.9 billion pigs in 33 countries where B. suis is endemic. 
There are only a few countries in the world that are officially free of the disease in some 
species, including Japan, Canada, Australia and New Zealand (OIE 2019), however human 
cases still can occur in these countries when people acquire the infection during international 
2 
 
travel or through contact with animal species that are reservoirs for the pathogen (Robinson 
2003).  
 
Brucellosis in humans results in an acute or sub-acute intermittent fever with malaise, 
prostration and anorexia, and without treatment the disease may continue for weeks or 
months progressing into a chronic form. Because of the non-specific clinical signs of 
infection, diagnosis should be confirmed by laboratory tests (Corbel et al. 2006). Brucellosis 
in animals results in significant economic losses because of abortions, reduced milk 
production, decreased reproduction rate and premature births (Seleem 2010). Although 
surveillance and control programmes have been implemented, the prevalence of brucellosis 
is increasing in some countries due to political, socioeconomic and sanitary factors (Gwida 
et al. 2010, Pappas et al. 2006). 
 
1.2 General information on the Iraqi Kurdistan Region 
1.2.1 Location 
  
Kurdistan “Land of the Kurds” is a defined geo-cultural region which includes the north-
western Zagros and the eastern Taurus mountain ranges. The contemporary use of Kurdistan 
includes large parts of eastern Turkey (Turkish Kurdistan), northern Iraq (Iraqi Kurdistan), 
north-western Iran (Iranian Kurdistan) and north-eastern Syria (Syrian Kurdistan) (Figure 
1.1) and these regions are predominantly populated by the Kurdish people or Kurds (Tasie 
2015, O'Shea 2004). The Iraqi Kurdistan Region borders Syria to the west, Iran to the east 
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and Turkey to the north. It is located in the northern part of the Republic of Iraq known as 
Kurdistan.  
 
The region lies between latitudes 34-42° and 37-22° north and between longitudes 42-25° 
and 46-15° east, and is traversed by the Sirwan River and the Tigris and its tributaries, the 
Great Zab and the Little Zab. The mountains have an average height of 2,400 meters above 
mean sea level (amsl) with the lowest point in the region is Kifri district, which has an 
elevation of 140 meters-amsl, and the highest point is the peak of Hasarost mountain in Erbil 
province, measuring 3607 meters amsl.  
 
In 1970 Iraqi Kurdistan gained autonomous status by agreement with the Iraqi Government 
and in 2005 its status was re-confirmed as an autonomous entity within the Federal Iraqi 
Republic (O'Leary et al. 2006). The Kurdistan Region is located in the north of Iraq and 
officially includes the three provinces of Erbil (Capital City of Kurdistan and also spelt 
Arbil), Sulaymani (also spelt as Sulaiminiyah) and Dohuk (Figures 1.2 and 1.3). However, 
Kirkuk province and some districts in Nineveh and Diyala provinces are also controlled by 
the Iraqi Kurdistan Government's forces (Peshmarga), as the majority of the population in 
these locations are Kurds and these are unofficially included within the Kurdistan Region. 
The provinces are subdivided into districts, sub-districts and villages. The Kurdistan Region 
is approximately 80,000 km² in size and forms 18% of the total area of Iraq. The total human 
population of Iraqi Kurdistan is estimated at 7 million, representing 17% of the total 
population of Iraq (BBC 2018, Kurdish-Institute 2007). Erbil, the capital of Kurdistan, is 




Figure 1.1: Map of Kurdistan 
https://ekurd.net/mismas/articles/misc2007/12/independentstate1825.htm   





Figure 1.2: Location of the Iraqi Kurdistan Region. 
https://www.institutkurde.org/en/info/iraqi-kurdistan-does-independence-beckon--





Figure 1.3: Location of the Provinces of Iraq 
https://en.wikipedia.org/wiki/Governorates_of_Iraq#/media/File:Iraqi_Governorates.svg 





      
The Kurdistan Region has an expanding economy built upon progressive economic policies 
and growing government transparency. With an abundant amount of proven natural resources 
and a large labour force, the Kurdistan Region has the potential to become a regional 
economic powerhouse. Investment opportunities span every sector, including oil and gas, 
electricity, energy, agriculture and the service industries (Soderberg and Phillips 2015, KRG 
2012). According to Iraqi Kurdistan Regional Government's data, Iraqi Kurdistan is 
estimated to contain around 45 billion barrels of oil, making it the sixth largest reserve in the 
world, and extraction of these reserves began in 2007. Other mineral resources that exist in 
significant quantities in the region include coal, copper, gold, iron ore, limestone, marble and 
zinc. Despite the total capital invested in agriculture related projects was only 1.43% of the 
total investment in Kurdistan’s economy in 2012, there are strong indicators that the industry 
will play a prominent role in shaping the future of the region (Abdullah 2013).  
 
1.2.3 Climate       
 
The climate of Kurdistan is considered to be continental and semi-tropical. It has wet, cold 
winters and dry, hot summers, except for the mountainous regions which have moderate 
summers with snow cover on the high mountains during the winter months. The rainfall 
pattern is influenced by the Mediterranean climate and the region is divided into three areas 
in terms of annual rainfall, which ranges from 350 to 1,200 mm (MAWR 2015, INSAM 
2003). The hottest months are from June to September (summer) with mean temperatures of 
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39-43°C and maximum temperatures of nearly 50°C. The autumn months of October and 
November are dry and mild with average temperatures of 24-29°C. The winter months are 
cold and wet with mean maximal temperatures of 7-13°C. In spring the mean temperatures 
range from 13-18°C in March to 27-32°C in May (MAWR 2015), and this season is the time 
when Kurds celebrate Nawroz, the Kurdish New Year (Katzman 2010). Water resources are 
largely associated with the quantity of rainwater and melting snow supplying the main water 
basins, along with water sourced from dams and reservoirs built upstream on rivers shared 
with Turkey, Syria and Iran (KRG 2012). However, the absence of international water 
sharing agreements between these countries results in a lack of certainty of available water 




A range of livestock species are present in the Kurdistan Region of Iraq, however sheep, 
goats and cattle are the most numerous and important, providing meat and milk, as well as 
skin and wool. There are approximately five million head of livestock and these are mainly 
found in the villages, sub-districts and districts of Kurdistan (KRG 2012, Personal 
Communication Dr Ali, Kirkuk Hospital). Sheep (3.25 million), goats (1.25 million) and 
cattle (0.42 million) represent 66.1%, 25.5% and 8.5% of the region’s livestock, respectively. 
Most livestock are in Sulaymani province (43.4% of the total livestock), followed by Dohuk 




Table 1.1: Number of livestock in the different provinces in the Kurdistan Region in 2010  
Provinces Sheep Goats Cattle Total 
Erbil  416,410 356,636 86,432 859,998 (17.5%) 
Sulaymani  1,423,383 525,786 179,990 2,130,659 (43.4%) 
Kirkuk 681,500 75,500 97,650 854,650 (17.3%) 
Dohuk  724,822 293,869 52,152 1,072,343 (21.8%) 
Total  3,246,115 1,251,791 416,224 4,914,130 
Percent of total 66.06% 25.47% 8.47% 100% 
 
(KRG 2012, Personal Communication Dr Ali, Kirkuk Hospital) 
 
1.3 Statement of the problem  
 
Brucellosis is a well-known, worldwide-distributed contagious zoonotic disease, which 
infects animals, including humans, through direct or indirect contact. Brucellosis remains a 
major zoonotic problem in the Middle East, and is a major economic burden to Iraq where 
the disease is endemic. The main source of human infection is through the consumption of 
raw milk and unpasteurised home-made white cheese (Seleem 2010), which is popular in 
Kurdistan. 
 
The first study on brucellosis conducted in Iraq was undertaken in humans, cattle, sheep and 
goats by Al Zahawi (1938) and brucellosis was recognised as an endemic disease in Iraq in 
1937. Between 1974 and 2004 several studies were undertaken in the northern provinces of 
Iraq in an attempt to determine the disease’s prevalence in livestock and humans. Nicoletti 
(1986) reported a seroprevalence of 1.0, 4.4, 3.1 and 10.8% in sheep, goats, cattle and 
humans, respectively in Iraq. Shareef et al. (1999) also investigated the seroprevalence in 
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animals and humans in Sulaymani City in the district of Qaradagh and reported that 1.34 and 
3.36% of sheep and goats were seropositive, respectively. Furthermore, in the City of 
Sulaymani, 65% of seropositive humans were females, although overall only 4.2% of the 
seropositive individuals were children (aged between 6 and 12 years) (Shareef et al. 1999). 
In another study 24.2% of 420 raw milk samples from the province of Basrah in the south of 
Iraq were seropositive to the milk ring test and overall 14.7% of samples were positive on 
culture (Abbas and Aldeewan 2009). The prevalence of human brucellosis has been shown 
to be higher in semi-rural areas (29.3%) than in rural or urban areas in Basrah (Yacoub et al. 
2006). 
 
Based on personal communications with representatives from the Iraqi Ministry of Health in 
Baghdad, the lowest number of cases of brucellosis in humans was in the late 1980s. 
However, during the 1990s, due to the economic sanctions resulting from the United Nations 
resolutions leading to reduced medical capability, there was a significant increase in the 
disease’s incidence. This, along with decades of unstable socio-economic and security-
political conditions, resulted in an increase in the disease in both animals and humans. In 
1995 the annual incidence of brucellosis was reported to have reached 88.5 cases/100,000 
people (Salih 2010). Subsequently the situation improved due to the Oil for Food and 




1.4 Aims of the current study 
 
The main aim of this project was to further our understanding of the epidemiology of 
brucellosis in sheep and goats in the Iraqi Kurdistan Region. This information is critical for 
the future development and implementation of effective control programmes.  
The specific aims of this study were to: 
1. Determine the seroprevalence of the disease in sheep and goats in the Iraqi Kurdistan 
Region. 
2. Identify risk factors for infection of sheep and goat flocks by administering a 
questionnaire to farmers in the Kurdistan Region whose small ruminants had been 
sampled. 
3. Conduct an economic analysis to determine the impact of the disease on productivity 
and evaluate the economic benefit in implementing a control programme that focused 
on vaccination. 
4. Conduct a retrospective study of human brucellosis in Iraq to describe the historical 




1.5 Significance of this study 
 
The data analyses and information acquired from this study will provide beneficial 
information on brucellosis to allow the development and instigation of preventive measures 
against the disease and implementation of suitable targeted surveillance programmes by the 




The main hypothesis of this study is that brucellosis is endemic in Kurdistan. It was also 
hypothesised that certain management and husbandry factors (such as purchasing new 
animals or water sources) increase the risk of infection, and control or elimination of these 






2.1 Definition and history 
 
Brucellosis is a well-known, worldwide distributed, zoonosis (Memish and Balkhy 2004). 
The disease is endemic in many animal species around the world and humans are infected 
primarily through the oral or percutaneous routes after contact with infected animals or their 
products (Doganay and Aygen 2003). It is caused by infection with bacteria belonging to the 
genus Brucella and was first recognised as a zoonotic disease by David Bruce when he 
cultured B. melitensis from the spleen of four soldiers who had died after displaying fever in 
Malta (Bruce 1887). Brucella abortus was subsequently isolated in 1897 from a cow that 
aborted in Denmark by Bang and consequently the disease was initially known as Bang’s 
disease (Meador 1988, Williams and McKusick 1954). Other members of the genus Brucella 
were subsequently discovered including B. suis, B. canis, B. ovis, B. neotomae, B. microti, 
B. ceti, B. pinnipedialis and B. inopinata (Scholz and Vergnaud 2013). 
 
Although Brucella species are not truly host specific (Robinson 2003), they do have a host 
preference, which is evident in their ability to establish a chronic infection and be transmitted 




2.2 Microbiological characteristics 
 
Brucella is small Gram-negative coccobacilli, 0.6 to 1.5 µm long by 0.5 to 0.7 µm wide. 
They are not truly acid-fast bacteria but resist decolourisation by weak acids, thus they stain 
red by the Stamp's modification of the Ziehl-Neelsen method (Corbel and Banai 1984). The 
morphology of Brucella is relatively constant, except in old cultures, where pleomorphic 
forms may be seen. They are arranged singly and less frequently in pairs or small groups. 
Brucella spp. are facultative intracellular, non-spore-forming and non-capsulated bacteria. 
Although they are considered to be non-motile, they carry all the genes, other than the 
chemotactic system, necessary to assemble a functional flagellum (Fretin et al. 2005). 
  
Brucella are aerobic, but some strains require an atmosphere containing 5-10% CO2 to grow, 
especially on primary isolation (Jensen et al. 1995). The optimal pH for growth varies from 
6.6 to 7.4 and culture media should be adequately buffered near pH 6.8 for the best growth. 
Although the optimal growth temperature is 36 to 38°C, most strains can grow between 20 
and 40°C (Corbel and Banai 1984). Brucella grow best on trypticase, soy-based or other 
enriched media with a typical doubling time of two hours. Species and biovars are 
differentiated by their CO2 requirements, ability to use glutamic acid, ornithine, lysine, and 
ribose; hydrogen sulphide production; growth in the presence of thionin or basic fucshin 
dyes; agglutination by antisera directed against particular lipopolysaccharide epitopes; and 




After 48-72h of incubation at 37°C, Brucella colonies are 0.5 to 1.0 mm in diameter with a 
convex and circular outline and a smooth, shiny surface (Alton et al. 1988). Smooth strains 
are transparent and pale yellow, resembling droplets of honey with a shiny surface when 
observed in transmitted light. Smooth colonies produce a yellow uniform suspension whereas 
rough colonies produce granular agglutinates (Padilla Poester et al. 2010, White and Wilson 
1951). Colonies were visible on nutrient agar after 3-5 days of incubation and they appear 
transparent or pale honey coloured when grown on serum dextrose agar (Alton et al. 1988). 
 
2.3 Brucella species 
 
There are 12 Brucella species currently recognised. The species that have been isolated from  
terrestrial animals and/or humans are: B. abortus, B. melitensis, B. suis, B. ovis, B. canis, B. 
neotomae, B. inopinata, B. vulpis, B. papionis and B. microti (Corbel 1997, Scholz et al. 
2016, Whatmore et al. 2014), while B. ceti and B. pinnipedialis have been isolated from 
marine mammals (Cloeckaert et al. 2001). The first six species are considered classical 
Brucella and within these species, seven biovars are recognised for B. abortus, three for B. 
melitensis and five for B. suis. The remaining seven species have not been further 
differentiated into biovars (Verger et al. 1987). The species of Brucella were named based 
on the host animal preferentially infected (Corbel and Banai 1984) with B. abortus primarily 
affecting cattle, B. melitensis sheep and goats, B. ovis sheep, B. suis pigs, B. canis dogs and 
B. neotomae desert woodrats (Neotoma lepida) (Blasco 1997, Corbel 1997, Corbel 1989). In 
addition, four more species have been identified from different animal types: B. ceti - 
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cetaceans; B. pinnipedialis - pinnipeds; B. microti – vole; and B. inopinata – humans (Blasco 
2011, Godfroid et al. 2011, Scholz et al. 2008a) (Table 2.1).  
 
Table 2.1: The species, biovars and natural hosts of Brucella. 
Species Biovars Natural host Zoonotic pathogen? 
B. abortus 1 – 6 & 9 Cattle Yes 
B. melitensis 1 - 3 Sheep and Goats Yes 
B. suis 
1 & 3 Swine Yes 
2 Hares No  
4 Reindeer, Caribou Yes 
5 Rodents Yes 
B. canis None Dogs and other canids Yes 
B. ovis None Sheep No 
B. neotomae None Desert woodrat No 
B. microti None Vole Unknown 
B. ceti None Cetaceans Unknown 
B. pinnipedialis None Pinnipeds Unknown 
B. inopinata None Unknown Unknown 
B. vulpis None  Red foxes Unknown  
B. papionis None  Baboons  Unknown  
(Godfroid et al. 2011, Scholz et al. 2016, Whatmore et al. 2014) 
 
2.3.1 Brucella melitensis 
 
Brucella melitensis was the first species of Brucella to be described (Seleem 2010). It causes 
abortions and orchitis in goats and sheep and Malta fever in humans (Megid et al. 2010). 
This is considered to be the most virulent species for humans, resulting in the highest 
morbidity with severe complications, including endocarditis, following infection (Corbel et 
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al. 2006). It is common in Latin America and the Middle East and in the latter region is 
considered a re-emerging pathogen (Seleem 2010, Pappas et al. 2006, Samartino 2002). 
Brucella melitensis also results in significant economic losses to the livestock industries 
through abortions (Radostits et al. 2000).  
 
Brucella melitensis is transmitted more readily from animals to humans than other members 
of the genus (Seleem 2010). Most cases of infection in humans are related to direct or indirect 
exposure to infected sheep or goats or their products (Sofian et al. 2008, Husseini and 
Ramlawi 2004). The best effective vaccine for control of brucellosis from infection with B. 
melitensis in small ruminants is Rev-1. This is an attenuated smooth strain of B. melitensis 
which also gives heterologous protection against infection with other Brucella species 
(Estein et al. 2009, Marin et al. 1990). 
 
2.3.2 Brucella abortus 
     
Brucella abortus was initially named Bacillus abortus by Bang in 1897, however it was 
subsequently renamed B. abortus in 1920 (Vassallo 1992). It is the aetiological agent of 
brucellosis in cattle, which is associated with premature calving, abortions and infertility in 
cattle, potentially resulting in significant economic losses. Although most species of Brucella 
are host specific, B. abortus can affect multiple species, including humans, particularly in 
situations where there is close contact between the animal species (Corbel et al. 2006). The 
disease is found in most cattle-raising regions of the world except for Japan, Canada, 
Australia, New Zealand, Israel and some European countries (Pal et al. 2017). 
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The primary hosts for B. abortus are cattle, elk (Cervus canadensis), bison (Bison spp.), 
African buffalo (Syncerus caffer), water buffalo (Bubalus bubalus) and camels (Camelus 
dromedarius) and a variety of other species, including sheep, horses, goats, raccoons, Rocky 
Mountain bighorn sheep (Ovis canadensis), dogs, foxes, wolves and opossums can become 
"spill-over" hosts in areas where the bacterium is endemic (Diaz Aparicio 2013, Corbel et al. 
2006, Alton et al. 1988, Corbel and Banai 1984). Brucella abortus, along with B. melitensis 
and B. suis, are recognised as potential military, civilian and agricultural bioterrorism agents 
(Valderas and Roop 2006). 
 
2.3.3 Brucella suis 
  
Brucellosis in pigs is primarily caused by the bacterium B. suis. The disease was first 
described by Traum in 1914 in swine herds in Indiana and was initially considered to be as a 
result of infection with pathogenic B. abortus, however the affecting organism was later 
named B. suis by Huddleson (Conger et al. 1999, Alton 1990). There are five biovars 
recognised, with biovars 1 to 3 affecting swine (Timoney et al. 1988). Biovars 1 and 3 have 
been detected in both domesticated and wild/feral pigs (Molin 2004). Biovar 2 currently 
occurs mainly in wild boar; however, this biovar can be transmitted to domesticated pigs and 
spreads readily in these herds. Biovar 4 is maintained in caribou and reindeer and can also 
infect moose, cattle, arctic foxes and wolves. Biovar 5, which is still poorly characterised, is 
believed to infect only murine species (Molin 2004, Timoney et al. 1988). Brucella suis have 
occasionally been reported in dogs, cattle, small ruminants, horses and other spill-over hosts. 
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Biovars 1 and 3 are both very pathogenic for humans (Conger et al. 1999); and, although 
biovar 2 and 4 have also been isolated from humans, infection occurs very rarely. 
 
Human infection is primarily limited to those exposed to the bacterium through their 
occupation, such as farmers and abattoir workers (Robinson 2003). In addition, recreational 
hunting of wild boars and consumption of meat from wild boar/feral pigs provides sufficient 
opportunity for the transmission of B. suis to humans. The potential for contact between wild 
boars/feral pigs and domestic swine also increases the likelihood of infection in domesticated 
pigs (Gibbs 1997, Meng et al. 2009). 
 
Abortion is the primary indicator of disease in pigs and this can occur at any stage of 
pregnancy (Al-Rawahi 2015), as well as clinical signs associated with atrophy of the 
epididymis, unilateral orchitis and infertility. There are reports of infection resulting in 
lameness associated with swollen joints, bursa and tendons and paralysis arising from abscess 
formation near the spine (Alton 1990). Brucella suis have been isolated from horses with 
septic bursitis, aborted equine foetuses and the internal organs of a mare with no obvious 
clinical signs of disease (Megid et al. 2010). Brucella suis was the first biological warfare 
agent developed by the USA in 1952 and was field-tested in organism-filled-bombs (M33 
cluster bombs) (Okutani 2007). However, because many infections in humans are 
asymptomatic with a low mortality, the agent was not considered an ideal biological weapon, 
although it could be used to target military personnel, civilians or food supplies (Christopher 




2.3.4 Brucella ovis 
 
Brucella ovis causes a genital infection in sheep resulting in epididymitis, increased lamb 
mortality and occasional abortions (Júnior et al. 2012, Ficapal et al. 1998, Blasco 1990). The 
bacterium was first isolated in New Zealand and Australia (Blasco 1990), and has also been 
reported in North and South America, South Africa, parts of Asia and European countries 
and probably occurs in most sheep-rearing regions of the world (Blasco 1990).  
 
Ewes rarely display clinical signs and only a small percentage of them abort; however, some 
ewes may develop placentitis that may result in the birth of weak lambs (Grilló et al. 1999). 
In sexually mature rams, B. ovis causes epididymitis, orchitis and infertility (West et al. 
2002). Venereal transmission via the ewe appears to be a frequent way of infection, but 
transmission from one ram to another ram by direct contact also occurs (Bushra et al. 2017, 
Blasco 1990). Infected ewes may also excrete B. ovis in milk and vaginal discharges and 
accordingly ewe-to-lamb transmission and ewe-to-ram transmission is also possible (Bushra 
et al. 2017). Although rams play a major role in the spread of the disease, eradication or 
control of B. ovis is only possible if both rams and ewes are included in any control 
programme (Blasco 1990). Until now no human cases have been reported, and consequently 
B. ovis is considered to be non-zoonotic. Although goats, deer and cattle have been 
experimentally infected with B. ovis, other than in sheep natural infection has only been 




2.3.5 Brucella canis 
   
Brucella canis was first described in 1966 in the USA when abortions in beagles were 
documented (Carmichael and Kenney 1968). It has since been reported in several countries 
in central and South America, along with Mexico and the southern states of the USA. In 
addition, it has been reported in commercial or research breeding beagle kennels in several 
other countries, including China and Japan, and has been reported sporadically in Europe 
(Wanke 2004, Carmichael 1990, Flores-Castro and Segura 1976). 
 
Brucella canis is mainly transmitted via sexual contact. The organism survives in the vaginal 
and uterine tissues of the bitch and can often be excreted for the life of the bitch. In male 
dogs, the bacteria resides in the testicles and seminal vesicles and can be shed in the semen 
or urine (Hollett 2006). Semen from infected males usually contains large numbers of 
inflammatory cells and abnormal sperm, especially during the first three months of infection. 
Infection can result in azoospermia in chronic infections (Carmichael 1990). 
 
Brucella canis is rarely a zoonotic organism (Hollett 2006, Carmichael and Kenney 1968). 
Canine brucellosis rarely is fatal, although it does result in reproductive failure. Clinical signs 
include infertility in males due to development of antibody against the sperm (Lucero et al. 
2010). Infected males often display no clinical signs, except in advanced cases where 
epididymitis, scrotal dermatitis, testicular atrophy, and infertility may be observed 




2.3.6 Brucella neotomae 
 
Brucella neotomae has only been isolated from desert rats (Neotoma lepida) in Utah, USA 
(Godfroid 2002). It has no known pathogenicity in any other animal species, including 
humans. This was recognised as a new species of Brucella on the basis of conventional genus 
speciation, including the organism’s behaviour on differential dye media, H2S production 
and CO2 requirements (Tiller et al. 2010).  
 
2.3.7 Marine mammal species 
 
The first marine mammal isolations of Brucella came from harbour seals (Phoca vitulina), a 
porpoise (Phocoena phocoena) and a common dolphin (Delphinus delphis) in Scotland (Ross 
et al. 1994), as well as from walruses (Odobenus rosmarus), whales and a broad range of 
marine mammal species from many parts of the world (Foster et al. 2002). The Brucella 
isolated (the Scottish strains) had biochemical properties which did not closely correlate with 
the descriptions of other recognised Brucella species, although it is possible that some or all 
of these strains will be identified as atypical cultures of existing species or biovars. 
Identification of these species to date has been based on staining, cultural characteristics, 
serology, metabolic phenotype and phage type (Vizcaíno et al. 2004, Clavareau et al. 1998, 




These bacteria appear to be widespread in marine mammal populations with seropositive 
animals detected in the Mediterranean Sea, North Atlantic Ocean, Arctic Ocean including 
the Barents Sea, and along the coasts of Peru, Australia, New Zealand and the Solomon 
Islands and the Atlantic and Pacific coasts of North America (Godfroid et al. 2012, Godfroid 
2002). Successful experimental infections of sheep and cattle have been reported (Rhyan et 
al. 2001) and several human infections have been documented, including three individuals 
with no occupational exposure to marine mammals. One marine mammal isolate was 
cultured from a laboratory worker with acute brucellosis (Brew et al. 1999). 
 
There is little information on the effects of brucellosis in marine mammals, although Brucella 
have been isolated from the reproductive organs of some marine species (Lopes et al. 2010) 
suggesting a potential to impact on fertility. Brucella isolates from marine mammals are 
genetically different from the terrestrial species. The name B. maris was originally suggested 
for all marine mammal isolates of Brucella based on the traditional naming system, with the 
division into two or more biovars based on host specificity (Moreno et al. 2012, Jahans et al. 
1997). Later on two new species names were proposed, i.e. B. cetaceae for isolates from 
cetaceans (whales, porpoises and dolphins) and B. pinnipedialis for strains from pinnipeds 
(seals, sea lions, and walruses) instead of B. maris (Cloeckaert et al. 2001). 
 
2.4 Brucellosis in humans 
 
Brucellosis in humans in some areas are usually associated with the consumption of 
unpasteurised milk or soft cheeses made from the milk of infected animals (Corbel et al. 
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2006). Brucellosis is also considered an occupational disease because of the higher incidence 
in people working with animals, such as farmers, veterinarians, laboratory workers and 
slaughterhouse workers. In these cases infection results from direct or indirect contact with 
infected animals and the bacterium enters via skin wounds or mucous membranes (LeJeune 
and Kersting 2010).  
 
The most common Brucella species to infect humans are B. melitensis, B. abortus and B. suis 
(Godfroid et al. 2011). Brucella canis has occasionally been reported to cause human 
infection; however human infection by B. neotomae and B. ovis has not been reported, and 
little is known about the capacity of B. inopinata to cause infection in humans, even though 
it was initially isolated from a human. Brucellosis is a serious zoonosis and results from direct 
or indirect contact with infected animals or their products. Although person-to-person 
transmission is rare, it may occur through sexual contact, tissue transfer (such as bone 
marrow and blood transfusion) and breastfeeding of infants. In addition, laboratory acquired 
Brucella infections due to accidental ingestion, inhalation, and mucosal or skin exposure to 
infected tissue specimens or cultures of virulent or attenuated Brucella species are potential 
health hazards (Thakur et al. 2012, Pike 1978). Brucellosis induces undulant fever, sweating, 
miscarriage, headaches, weakness, depression, anaemia and muscle pain (Al Dahouk et al. 
2003). 
 
Human brucellosis is a very old disease being first reported in 1887. It has minimal mortality 
and is one of the commonest zoonotic diseases worldwide (Pappas et al. 2006) with an 
estimated 833,000 (95% uncertainty interval (UI) 337,929 - 19,560,440) cases of brucellosis 
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due to foodborne routes each year (Kirk et al. 2015). Brucellosis is also an important cause 
of travel-associated morbidity (Gautret et al. 2013). Despite being controlled or eradicated 
from some developed countries, the disease remains endemic in many parts of the world, 
including Latin America, the Middle East, Spain, parts of Africa, and western Asia (Memish 
and Balkhy 2004). The Middle East has traditionally been considered an endemic area for 
the disease, with five Middle Eastern countries (Syria, Iraq, Turkey, Iran and Saudi Arabia) 
being ranked in the top ten countries in the world for the highest incidence of human 
brucellosis (2nd, 4th, 5th, 6th and 7th respectively) (Hotez et al. 2012, Pappas et al. 2006). 
 
The incidence of brucellosis in humans varies widely, not only between countries but also 
within countries. There is an obvious lack of high quality scientific data relating to the 
incidence of brucellosis in humans globally, with the majority of data coming from north 
Africa and the Middle East (Dean et al. 2012a). A lower disease incidence is seen in 
developed countries when compared to low and middle income countries. However, 
brucellosis can still target specific sub-groups of developed countries, including Hispanic 
communities of low socioeconomic status in the USA (Doyle and Bryan 2000), Turkish 
immigrants in Germany (Al Dahouk et al. 2007) and Australian pig hunters who are at risk 
of infection from B. suis (Massey et al. 2011, Young 1995). These findings indicate that 
brucellosis remains a disease of potential public health importance, even in developed 
countries. It is well accepted that nearly every case of human brucellosis has an animal origin 




2.5 Sensitivity and survival of Brucella in the environment 
 
Several studies have commented on the relatively high persistence of Brucella spp. under 
suitable conditions compared with most other non-spore forming pathogenic bacteria (Salih 
2010, Bossi et al. 2004). Thus when temperature, pH, and light conditions are favourable 
(high humidity, low temperature and absence of direct sunlight), Brucella may retain their 
infectivity for several months in water, faeces, liquid manure, aborted foetuses and foetal 
membranes, hay, wool, building construction materials, clothing and equipment (Salih 
2010). Furthermore, Brucella can withstand drying, particularly in the presence of extraneous 
organic material, and will remain viable in dust and soil for up to two months. Survival is 
prolonged at low temperatures, especially below 0°C (EC 2001). The reported survival times 
of Brucella are summarised in Tables 2.2 and 2.3.   
 
Brucella are sensitive to exposure to heat and most disinfectants, however they can survive 
in the environment for up to two years under ideal conditions. This long survival can result 
in them being a serious threat to both humans and other animals (Bossi et al. 2004). Brucella 
may be killed at temperature of 60°C for 10 minutes, although the large numbers present in 
some heavily contaminated environments and laboratory cultures can require more drastic 
heat treatment to ensure their inactivation (Barer and Irving 2018). Fortunately infected milk 
is rendered safe by pasteurization at 72°C for 1 minute (EC 2001). Brucella are very sensitive 
to direct sunlight, and moderately sensitive to acid, so that they tend to die in sour milk and 
in hard cheeses that have undergone lactic acid fermentation (Barer and Irving 2018). 
Treatment with 2.5% sodium hypochlorite, 2-3% caustic soda, 20% freshly slaked lime 
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suspension or a 2% formaldehyde solution will destroy Brucella within one hour on 
contaminated surfaces (EC 2001). 
 
Table 2.2: Survival time of Brucella under different environmental conditions and in 
different media. 
Medium Condition Survival time 
Ice           -4ºC 4 months 
Water (laboratory)    20ºC 2.5 months 
Lake water 
37ºC, pH 7.5 < 1 day 
8ºC, pH 6.5 > 57 days 
Soil autumn, 90% humidity 48-73 days 
Urine 
37ºC, pH=8.5 16 h 
8ºC, pH=6.5 6 days 
Manure 
Summer 1 day 
Winter 53 days 
Manure (liquid) 
Summer 108 days 
Winter 174 days 
Slurry (animal waste) Tank > 8 months 
Abdominal fluid, sheep - 10-30 min 
Wool - 110 days 
Hay  - Several days to a month 
Street dust  - 3-44 days 
Raw milk 
25-37ºC 24 h 






Table 2.3: Duration of survival of B. melitensis and B. abortus in various dairy products. 





5-15 seconds NA 71.7 B. abortus 
Milk:  
 
<9 hours 4.00 38 B. abortus 
24 hours NA 25 - 37 B. abortus 
18 hours  0 B. abortus 
6 weeks NA 4 B. abortus Ice cream 
 Cream:  
 
4 weeks NA 4 B. melitensis 
30 days NA 0 B. abortus 
Butter 
142 days NA 8 B. abortus 




15 - 100 days NA NA B. melitensis 
4 - 16 days NA NA B. melitensis Feta 
< 90 days NA NA B. melitensis Pecorino 
20 - 60 days NA NA 
B. melitensis 
& B. abortus 
Roquefort 
< 21 days NA NA B. abortus Camembert 
44 days NA NA B. melitensis Eritrean 
6 months NA NA B. abortus Cheddar 
1 - 8 weeks NA NA B. melitensis White 
< 4 days 4.3 - 5.9 17 - 24 B. abortus 
Whey: 
>days 5.4 - 5.9 5 B. abortus 
(Memish and Balkhy 2004, EC 2001) 
NA: not-applicable or no information 
 
Fermentation of unpasteurised milk into products such as cheese or yogurt does not destroy 
Brucella (Estrada et al. 2005) and Iraqi yogurt may contain viable Brucella organisms 
(Personal Communication Dr Ali, Kirkuk Hospital). It has been hypothesised that homemade 
cheeses in many rural areas may lead to infection of humans if they are made from Brucella 
contaminated milk (Yumuk and O’Callaghan 2012). 
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2.6 Clinical signs of brucellosis 
 
Although there is no standard classification of brucellosis in both animals and humans, some 
authors have classified the disease according to the duration and severity of illness as 
subclinical, acute, sub-acute and chronic (Ulu Kilic et al. 2013, Doganay and Aygen 2003, 
Pappas et al. 2005). In contrast Ulu Kilic et al. (2013) classified the disease into acute, chronic 
and localised forms, while Goldbaum et al. (1992) classified the disease as either active or 
inactive. It is necessary to isolate the causative agent or demonstrate some type of specific 
serological response in order to mention these terms. 
 
Brucellosis in animals results in significant economic losses because of reduced milk 
production, abortions, decreased reproduction rate, intrauterine infection with foetal death 
and premature births (Seleem 2010). In cattle, brucellosis is generally a disease of females 
but entire males can also be infected with the bacteria localizing in the testicles resulting in 
orchitis (Diaz Aparicio 2013). Infected cows usually abort only once, and subsequent calves 
may be born either weak or healthy, although some infected cows will not exhibit any clinical 
signs. Because of the non-specific clinical signs of infection, diagnosis should always be 
confirmed by serological tests (Corbel et al. 2006). 
 
Brucellosis in humans is a systemic infection with a range of clinical signs ranging from 
asymptomatic disease to severe or very rarely a fatal disease. The incubation period is usually 
one to four weeks; although occasionally, it may be as long as several months. The primary 
manifestations are acute febrile disease (with or without signs of localization) and chronic 
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infection with clinical and laboratory features that vary widely (Ulu Kilic et al. 2013). 
Symptoms in affected humans include intermittent or irregular fever of variable duration (the 
most common symptom), profuse sweating, chills, diffuse or localised arthralgia, weight loss 
and generalised pain (Bossi et al. 2004). Fever can be spiking and accompanied by rigors, if 
bacteraemia is present, or may be relapsing, mild, or protracted. Chronic brucellosis can 
develop from acute infection, or it may develop directly without a prior acute phase 
(Bukharie 2009). Infection among children is usually more benign than in adults with less 
severe complications and a better response to treatment (Akhvlediani et al. 2010). Jennings 
et al. (2007) reported that the majority of patients delay seeking medical attention and, 
because of the non-specific nature of the symptoms, diagnosis is often delayed.  
 
Infection in humans with B. melitensis results in a more severe infection than B. abortus, 
however infection with B. suis can be as severe as B. melitensis. Brucella canis is infrequently 
associated with human disease and reported cases have usually been mild. Brucella 
melitensis generally results in an acute infection whereas the infections with other species 
are usually sub-acute and prolonged (Dean et al. 2012b, Young 1995). 
 
2.7 Pathogenesis and transmission 
 
Infection with Brucella usually occurs following ingestion or inhalation of the organisms 
(Corbel 1989). The bacteria are transported through the mucosal epithelium either free or 
within phagocytic cells to the regional lymph nodes (Paixão et al. 2009). The subsequent 
multiplication and spread of Brucella in the lymph nodes, bone marrow, spleen, mammary 
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glands, liver and sex organs occurs via macrophages. After replication, organisms are 
released with the help of haemolysins and induced cell necrosis. Brucella survive within 
neutrophils following phagocytosis and also can replicate in macrophages and phagocytes 
(Ko and Splitter 2003). Survival in macrophages is considered to be a key factor in the 
establishment of chronic infections, allowing the bacteria to escape the extracellular 
mechanisms of the host defences, such as complement and antibodies (Ko and Splitter 2003). 
 
Brucella can survive for several days in milk, for weeks in ice cream and months in butter, 
consequently it is recommended that these products are made from pasteurised milk (Table 
2.3) (Memish and Balkhy 2004). The sale of dairy products from unpasteurised milk is a key 
cause of infection in urban populations and travellers visiting areas where the disease is 
endemic (Makita et al. 2010, Al Dahouk et al. 2005). In addition, meat from infected animals 
may also be a source of infection if not cooked adequately (Corbel et al. 2006). Some 
particular food habits, such as eating aborted foetuses as occurs in Ecuador, is also likely to 
increase the risk of brucellosis in humans (Godfroid et al. 2005). 
 
Infected livestock, such as cattle, sheep, goats and pigs, are the primary source of brucellosis 
for humans with transmission occurring through contact with infected animals or their 
materials (Corbel et al. 2006). Brucella is an occupational disease that mainly affects 
butchers, veterinarians, and slaughterhouse workers through contamination of skin wounds 
(LeJeune and Kersting 2010). Most cases of B. melitensis infection can be related to direct 
or indirect exposure to infected sheep or goats or their products; with occasional transmission 
from other animals, such as members of the Bovidae and Camelidae genera (Corbel 1989). 
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Mothers who are breast-feeding may transmit the infection to their infants, and sexual 
transmission has also been reported, but these are of minor importance compared with other 
routes of transmission (Arroyo Carrera et al. 2006, Corbel et al. 2006, Lubani et al. 1988). 
 
Many factors can influence the prevalence of brucellosis in livestock, such as the prevailing 
environmental conditions, sex, age, species, diagnostic tests used and geographical location 
of the study (Crawford et al. 1990). Brucella spp. are usually transmitted between animals 
by direct or indirect contact with an infected animal through aborted foetuses, placenta, 
vaginal discharges and foetal fluids. In addition, dogs can play a role in the contamination of 
the environment by feeding upon infected aborted foetuses and/or dragging them to “clean” 
areas (Baek et al. 2003). The main route of entry for Brucella spp. is oral arising from the 
ingestion of food or water contaminated with secretions or aborted foetal remains from 
infected animals (Samartino and Enright 1993, Crawford et al. 1990). While semen can be 
contaminated with the bacteria in infected bulls, artificial insemination is of less importance 
unless the semen is sourced from an infected bull (Corbel et al. 2006). Infected cows shed 
Brucella in their milk and this is key in the transmission to calves. In dairies, milking is 
another mode of transmission that must be considered because the bacteria are highly likely 
to be transmitted from cow-to-cow if the same teat cups are used for milking. For this reason, 
it is recommended that healthy cows be milked first and infected cows last (Samartino 2003, 
Samartino and Enright 1993). In extensively managed goat and sheep farms, it is common 
practice for flocks to share pasture and watering points. Such mixing of animals is a risk 
factor for the spread of disease from infected to free flocks, making control more challenging 
(Samadi et al. 2010). The purchase of infected animals and introduction to a disease-free herd 
is the most common means of disease introduction (Mee et al. 2012). In contrast to terrestrial 
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animals, the transmission of Brucella in marine mammals is poorly understood, however it 
has been hypothesised that the pathogen may be acquired via the food chain (Godfroid et al. 
2011, Godfroid 2002).  
 
2.8 Epidemiology of brucellosis 
 
Although brucellosis has a worldwide geographical distribution, it remains a particularly 
important disease of livestock and a public health problem in the Mediterranean Region, 
Africa, the Middle East, Asia, India and South America (Figure 2.1 and Table 2.4) 
(Benkirane 2006, Corbel et al. 2006, Pappas et al. 2006). The geographical distribution of 
brucellosis is always changing, with new foci emerging or re-emerging (Seleem 2010). The 
epidemiology of human brucellosis has changed dramatically over the last 25 years because 
of socioeconomic and political reasons and the various sanitary control measures 
implemented, in addition to increased international travel by a larger population of people 
(Pappas et al. 2006). New foci of human brucellosis have emerged, particularly in central 
Asia, while the situation in certain countries of the Middle East has rapidly worsened (Pappas 
et al. 2006). Brucellosis is an important disease of humans and domestic animals in central 
America (CA), where swine and bovine brucellosis caused by B. suis and B. abortus, 
respectively, have been identified in all CA countries, while caprine and ovine brucellosis 
caused by B. melitensis has been detected in Guatemala along with other countries in the 





Figure 2.1: Distribution of B. melitensis of domestic and wild animals between July and 
December 2010. 
http://www-old.caribvet.net/fr/diseases/brucellosis/distribution-g%C3%A9ographique      
(Accessed 26 February, 2019) 
 
Traditionally the Middle East has been considered an endemic area for brucellosis, and 
although human brucellosis is a notifiable disease in some countries of the Middle East, it is 
often under-reported and/or unrecognised (Refai 2002). However, five of the 10 countries 
with the highest incidence of human brucellosis in the world are located within the region 
(Pappas et al. 2006). The estimated incidence of infection in humans varies widely between 
countries from <0.03 to >160 per 100,000 people per year (Pappas et al. 2006, Taleski et al. 
2002) (Table 2.4); however, the actual number of human cases of brucellosis is unknown and 
is believed to be much more than the officially reported number (Refai 2003). In Iraq 
brucellosis has been recognised in humans, cattle, sheep and goats since the 1930’s (Al 
Zahawi 1938). 
 
Although brucellosis occurs worldwide in animals, some countries are free of the disease in 
specific species (Seleem 2010, Corbel 1989), although disease may occur in people returning 
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from countries where the disease is endemic (Al Dahouk et al. 2005). Brucella abortus in 
animals has been eradicated from Sweden, Japan, Finland, The Netherlands, Cyprus, 
Norway, Denmark, Canada, United Kingdom, Australia and New Zealand (OIE 2019, 
Seleem 2010). While B. melitensis has never been detected in some countries (Robinson 
2003). 
 
Table 2.4: The incidence of brucellosis in humans per 100,000 people per year by country. 
Country Study level Incidence per 100,000 people per year 
Egypt  Local regions 0.3 – 70.0 
Iran Local regions 0.7 – 141.6 
Iraq Local regions 52.3 – 268.8 
Jordan  National 25.7 – 130.0 
Kuwait National 3.4 
Lebanon National 5.0 
Oman Local regions 11.0 
Palestine Local regions 8.0 
Saudi Arabia National 137.6 
Syria National 160.3 
Turkey Local regions 11.9 – 49.5 
United Arab Emirates National 4.1 
Kyrgyzstan National 88.0 
Chad Local regions 34.9 
Germany National 0.03 
Greece Local regions 4.0 – 32.5 
Italy National 1.4 
Argentina Local regions 12.8 
Mexico Local regions 25.7 




Infection of sheep with B. melitensis is endemic in the Mediterranean region, particularly 
along the eastern and northern shores. It is found throughout central Asia, south to the 
Arabian Peninsula and as far as Mongolia, India and Africa (EC 2001) (Figure 2.1). Although 
the main sources of infection are sheep, goats and their products, B. melitensis has emerged 
as an important problem in cattle in Saudi Arabia, Kuwait and some Southern European 
countries (Álvarez et al. 2011, Benkirane 2006). Similar cross-species transmission has been 
reported in Paraguay and some South America countries, where B. suis biovar 1 has become 
established in cattle (Baumgarten 2002, Samartino 2002).  
 
Table 2.5: Seroprevalence of brucellosis in small ruminants in some Middle Eastern 
countries. 
Country Animal host % Seropositive Source 
Egypt Sheep & goats 2.4 & 8.2 Benkirane (2006) 
Iran goats 10.18 Gul and Khan (2007) 
Iraq Sheep & goats 1.3 & 3.4 Shareef et al. (1999) 
Israel Sheep 8.2 Benkirane (2006) 
Jordan Sheep 2.2 Al-Talafhah et al. (2003) 
Kuwait Sheep 2.4 Benkirane (2006) 
Oman Sheep & goats 0.14 & 0.42 Al-Rawahi (2015) 
Saudi Arabia Sheep & goats 6.5 & 9.7 Gul and Khan (2007) 
Syria Sheep 12.87 Darwish and Benkirane (2001) 
Turkey Sheep 11.5 Yumuk and O’Callaghan (2012) 
UAE Sheep & goats 8.4 Mohammed and Shigidy (2013) 





2.9 Diagnosis of brucellosis 
 
The diagnosis of brucellosis on presenting clinical signs alone is difficult because of the 
variety and non-specific nature of the signs (Lulu et al. 1988) and therefore diagnosis must 
be confirmed through the use of laboratory tests (Corbel et al. 2006). Fast and accurate 
diagnosis of brucellosis in humans and other animals is critical as misdiagnosis or a delay in 
diagnosis may result in treatment failure, disease spread, the disease progressing to a chronic 
nature, relapses or focal complications (Seleem 2010, Al Dahouk et al. 2007). Diagnostic 
tests can be applied with different goals: confirmatory diagnosis; screening or prevalence 
studies; certification; and in countries where brucellosis is eradicated, surveillance in order 
to avoid the reintroduction of brucellosis through importation of infected animals or animal 
products. However the validation of such diagnostic tests can be challenging, particularly in 
wildlife (Godfroid et al. 2010).  
 
2.9.1 Laboratory diagnosis  
 
A number of techniques have been developed to diagnose brucellosis in humans and other 
animals. Definitive diagnosis of the disease is based on cultural or serological techniques or 
both, and a range of serological tests are widely used for the diagnosis of brucellosis (Etman 
et al. 2014). There are several challenges facing the diagnosis of brucellosis using serological 
tests: firstly antibodies from a range of other microorganisms, such as Yersinia enterocolitica 
O:9 and Escherichia coli O157:H7, Stenotrophomonas maltophilia and Salmonella spp., can 
cross-react with diagnostic tests resulting in false positive results (Matope et al. 2010, Nielsen 
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et al. 2004, Alton et al. 1988); secondly most serological tests are not capable of detecting 
antibodies during the early stage of infection or in chronic or latent carriers (Al-Rawahi 
2015); thirdly most serological tests cannot differentiate between naturally infected and 
vaccinated animals (Godfroid et al. 2010); and finally some tests are expensive and require 
experienced technicians and expensive equipment and consequently are not suitable for 
routine use in developing nations (Dauphin et al. 2009). Although these factors can limit the 
usefulness of serological tests in control and eradication programmes, serological tests do 
offer the advantage of speed, large numbers of samples can be tested and they are relatively 
inexpensive (WHO 2009). Many studies have highlighted the advantages of using PCR tests 
and culturing for individual animals (Gwida et al. 2010); however these are not practical for 
control programmes or for testing large populations of animals (Ghodasara et al. 2010). 
 
2.9.1.1 Isolation of Brucella by culture 
 
Isolation of Brucella from aborted foetuses, still-births, uterine discharges, blood, lymph 
nodes, cerebrospinal fluid or bone marrow from both humans and animals remains the gold 
standard for the diagnosis of brucellosis (Alton et al. 1975a). However, culture cannot 
practically be used as a screening test, due to slow growth of the organisms and the 
technique’s low sensitivity (Franco et al. 2007). The sensitivity is influenced by: the quantity 
of pathogen in the clinical samples; the methods used for culturing; the individual laboratory 
practices; the use of antibiotics prior to culture of the media; the cultured strain and species 
(B. abortus is harder to culture from clinical samples than B. melitensis); and the stage of 
infection. The sensitivity can range from 15 to 70% in human cases; however, higher values 
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have been reported when using the lysis centrifugation technique (91%) (Seleem 2010, Glynn 
and Lynn 2008). Although some authors believe that culture is the only definitive method of 
diagnosing infection (Gotuzzo et al. 1986), it is expensive, time-consuming, has low 
sensitivity and can be influenced by the presence of contaminants (Blasco et al. 1994). In 
addition, the pathogenic nature of some B. species means that laboratory and field staff must 
take adequate precautions to prevent infection. Hence, in the laboratory, Brucella spp. or 
potential infectious materials should always be handled in biosafety level 3 cabinets 
(Yagupsky and Baron 2005, Staszkiewicz et al. 1991). Due to these reasons the diagnosis of 
brucellosis in most control and eradication programmes has been based on the results of 
serological assays (Corbel et al. 2006). 
 
2.9.1.2 Diagnosis through the use of serological assays      
 
Several serological tests can be used to detect Brucella specific antibodies in individual 
animals or herds including the buffered acidified plate antigen test (BAPAT), Rose Bengal 
plate test (RBT), the complement fixation test (CFT), buffered plate agglutination test and 
enzyme-linked immunosorbent assay (ELISA) (Weynants et al. 1996a). One major 
disadvantage with serological tests is the occurrence of false-positive and false-negative 
reactions due to the tests specificities and sensitivities being less than 100% (Nielsen and Yu 
2010). 
 
The most widely used tests for the serological diagnosis of brucellosis in small ruminants are 
the RBT and the CFT. However, both tests lack specificity when used for testing sera from 
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goats and sheep vaccinated with Rev-1, although this problem is reduced if the vaccine is 
administered via the conjunctival route (Díaz-Aparicio et al. 1994, De Bagüés et al. 1992, 
Fensterbank et al. 1982). The sensitivity of the RBT and the indirect ELISAs are better than 
that of the CFT, and these tests detect antibodies raised against smooth lipopolysaccharides 
(S-LPS) (Blasco et al. 1994). Mizanbayeva et al. (2009) reported that the immuno-
chromatographic Brucella specific immunoglobulin lateral flow assay (LFA) was a simple, 
rapid test for the detection of specific antibodies in a variety of human body fluids. Moreover, 
it is highly specific and sensitive, and the application of it does not need specific equipment, 
experienced personnel, electricity or a refrigerator, making this test ideal for use in poor 
countries (Anumolu 2015). Serological tests developed for detecting antibodies to B. abortus 
in cattle have also been used to detect B. melitensis in small ruminants as no serological test 
has been developed only for B. melitensis (Godfroid et al. 2010). 
 
2.9.1.2.1 Rose Bengal Plate Test (RBT) 
 
The RBT is a single dilution serum agglutination test and is often used to screen entire herds 
of ruminants for evidence of infection  (Kaltungo et al. 2014, Ali 2012). The test was 
developed for the diagnosis of bovine brucellosis, and is internationally recommended for 
the screening of brucellosis in small ruminants (Blasco et al. 1994, MacMillan 1990). The 
principle of the test depends on the development of an antigen-antibody reaction leading to 
agglutination, however the quality of the antigen can affect the sensitivity of this test (Alton 




Sharma (2016) reported that the RBT was capable of detecting both IgG and IgM. However 
the test can result in false positive reactions up to 6 months after animals have been 
vaccinated, although these cross-reactions decrease with time. Such false positive reactions 
result in challenges in the diagnosis of brucellosis, especially in endemic areas (Kaltungo et 
al. 2014). False positive reactions with the RBT may also arise due to cross-reactions with 
antibodies against Salmonella spp., Y. enterocolitica and V. cholera (Kaltungo et al. 2014, 
Nielsen et al. 2004). The test is easy to run with little equipment required and has been widely 
used in the field as a pen-side test (Corbel et al. 2006). However its sensitivity may be 
affected by high ambient temperatures, and in such situations the test is best run under 
standardised conditions in a laboratory (Blasco et al. 1994).  
 
2.9.1.2.2 Complement Fixation Test (CFT) 
 
The CFT has been widely used in control and eradication programmes for brucellosis 
(MacMillan 1990, Alton et al. 1975b). It is of particular value in differentiating active 
infection from a vaccine response arising from the use of a live vaccine and the CFT mostly 
identifies IgG antibodies in the later stages of infection (Alton et al. 1975). Although the 
sensitivity of the RBT is sufficient for the surveillance of free areas at the flock level, the 
CFT should be used in conjunction (in parallel) with the RBT in infected flocks to improve 
the sensitivity of diagnosis (García-Bocanegra et al. 2014). The CFT has a higher specificity 
compared with the RBT, Indirect ELISA and SAT (serum agglutination test) (Dohoo et al. 
1986) and has been reported to have a higher sensitivity and specificity in adult cows 
vaccinated with S19 than the rivanol and milk ring tests (Huber and Nicoletti 1986). However 
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the CFT does have several disadvantages including the need to use an extremely labile 
reagent (complement), the occurrence of anti-complementary activity, technical demands, a 
failure to detect a response in early stages of the disease and subjectivity of the interpretation 
of low titres (Lucero et al. 1999). False negative reactions may also occur due to the test only 
being able to detect antibody at least two weeks after infection (Sutherland 1980). 
 
2.9.1.2.3 Serum Agglutination Test (SAT) 
      
The simple agglutination test was developed more than 100 years ago to diagnose brucellosis 
(Nielsen 2002) and was the standard test used before the RBT was developed. The SAT 
detects IgM more efficiently than IgG and consequently is ideal for the detection of early 
infection. However the SAT can generate false positive reactions if animals have other 
illnesses including tularaemia, salmonellosis, cholera and myeloma (Allan et al. 1976). False 
negative in humans may also occur early in the course of the disease [cited by Al-Attas et al. 
(2000)]. In endemic areas, a Brucella antibody dilution of 1:320 or 1:640 is considered 
significant with this test, while in areas where the disease is not endemic a lower antibody 
dilution of 1:160 is considered to be the cut-off point for positivity (Pappas et al. 2005). The 
SAT has some other disadvantages including the potential for prozone phenomena that can 




2.9.1.2.4 Enzyme-linked Immunosorbent Assay (ELISA)  
 
ELISAs have been used to detect serum antibodies following vaccination and for naturally 
infected animals, can detect antibody in milk and can detect all isotypes of antibodies 
(Godfroid et al. 2010, McGiven et al. 2003, Al-Shamahy and Wright 1998). These tests have 
several advantages including high test sensitivity and specificity, they are not affected by 
haemolysis or anti-complementary effects, and they are commercially available and are not 
complicated to perform (Memish et al. 2002, Reynolds 1987). However there is a need for 
an ELISA plate reader and the test is not cheap compared to other tests, such as the RBT 
(Sutherland et al. 1986).  
 
Most ELISAs used for the diagnosis of brucellosis are iELISAs (indirect ELISAs); however 
the competitive ELISA (cELISA) is gaining prominence for the diagnosis of brucellosis. This 
ELISA is a multi-species assay that can differentiate between antibodies induced by natural 
infection from those induced by vaccination in cattle (Nielsen et al. 1996, Nielsen et al. 
1995). The cELISA is quick to perform, but does require specific monoclonal antibody to 
the S-LPS, however it is commercially available (Marin et al. 1999). According to Nielsen 
et al. (1995), the ELISA is the most suitable assay for the diagnosis of brucellosis in 
individual animals because of its ease of performance and its high sensitivity. Hornitzky and 
Searson (1986) reported that the usefulness of the ELISA was highlighted in cattle that were 
culture positive, had a low CFT titre or were non-vaccinated RBT negative reactors animals. 
False positive reactions can occur due to an immune response of the animal to another 
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microorganism which shares epitopes with Brucella spp. for instance, Y. enterocolitica O:9 
[cited by Lucero et al. (1999)]. 
 
In humans the most important factor affecting immunoglobulin titres was the duration of the 
disease at hospital admission. Patients with a longer duration of illness before hospitalization 
had relatively low ELISA IgM titres, whereas IgG titres were relatively high. An ELISA is 
the most sensitive serological test in humans and is useful to monitor antibodies in patients 
undergoing treatment (Clavijo et al. 2003). The test is commonly used in endemic areas to 
detect antibody in affected animals and people prior to the development of clinical signs or 
symptoms (Seleem 2010). In the first days of infection, IgM antibodies to the S-LPS 
predominate, after which there is a switch to IgG isotype synthesis in individuals who have 
not received treatment. This different timing of antibody production allows discrimination 
between patients (people) with acute or chronic brucellosis (Marrodan et al. 2001, Reddin et 
al. 1965). In contrast the RBT, SAT and CFT cannot discriminate between the two classes 
of antibodies because, although IgM antibodies specific to the S-LPS are efficient 
agglutinins, IgG antibodies can behave as either agglutinating or non-agglutinating 
(incomplete) antibodies and both classes are active in the CFT. Consequently, supplementary 
tests such as the iELISA with S-LPS and anti-IgM and anti-IgG conjugates are used for these 




2.9.1.2.5 The Mercapto-ethanol Test (ME Test)  
 
The mercapto-ethanol test (ME Test) is not as sensitive as the SAT; however the results 
correlate better with the activity of the disease, and it is considered superior to other tests in 
determining the efficacy of antimicrobial therapy in humans (Madkour and Kasper 2001a). 
Mercaptans (2-mercaptoethanol) or dithiothreitol cleave disulphide bonds of IgM resulting 
in loss of agglutination activity. This can be used to distinguish between persistent and early 
infection in human brucellosis (Young 1991, Buchanan and Faber 1980). A titre of 1/20-1/40 
of the ME test is indicative of active Brucella infection (Al-Shamahy and Wright 2001). 
However the test requires experienced technicians and the results can be difficult to interpret 
and therefore it is rarely used today (Brinley-Morgan 1967). 
 
2.9.1.2.6 Milk Ring Test (MRT)  
 
The milk ring test is a simple test using antigen of whole cell haematoxylin stained killed 
Brucella that can detect antibodies attached to the fat globules of the milk of infected cows 
(Huber and Nicoletti 1986, Sutra et al. 1986). The antigen-antibody complex that forms when 
the antigen is added to the milk rises to the surface to form a ring in the cream layer (Nielsen 
and Yu 2010). Corbel et al. (2006) confirmed that the sensitivity of the test was reasonable; 
however false-negative reactions have been reported arising from a variety of conditions 
affecting the milk including mastitis, colostrum and milk at the end of the lactation cycle 
(Nielsen and Yu 2010). Because of these concerns the MRT is recommended as a screening 
test for bovine brucellosis (OIE 2000). In addition, in areas where the prevalence of 
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brucellosis is low, where animals have been vaccinated with strain 19 or in animals with 
mastitis, the MRT has been found to be less useful (Thoen et al. 1995). However, the MRT 
does have the advantages that it is a cheap, simple test that can be used for screening dairy 
herds by non-skilled personnel, and it is usually used in conjunction with other tests (Nielsen 
and Yu 2010). 
 
2.9.1.2.7 Rivanol Test  
 
The rivanol test depends upon the precipitation of serum protein by rivanol dye and can help 
differentiate naturally infected from vaccinated cattle (Alton et al. 1988). Huber and Nicoletti 
(1986) reported the presence of false-negative reactions with this test in cattle, especially 
when they had been vaccinated with B. abortus S19 at a young age. According to Mikolon 
et al. (1998) the test had a high specificity (99%) and a good sensitivity (90%) (1:25 dilution) 
and as a result of the low false positive rate it was concluded that the test was useful for 
detecting infected goats experimentally challenged with B. melitensis.  
 
2.9.1.2.8 Coombs Test 
 
The Coombs test, which is also called the antihuman globulin test (AHG), has mainly been 
used to detect infection in people. However it has also been used to confirm the results of the 
CFT in cattle (Sutherland 1980). This test can have a high percentage of false positive 
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reactions in vaccinated animals; however, it has been demonstrated to be effective in 
detecting chronic carriers (Brinley-Morgan 1967).  
 
2.9.1.3 Molecular detection and identification of Brucella spp. 
2.9.1.3.1 Polymerase chain reaction (PCR) 
 
The PCR is a technique used widely in medical and biological research laboratories 
throughout the world (Rahman et al. 2013b). It has been used to study the epidemiology of 
brucellosis and to differentiate between species and strains through differences in Brucella 
DNA (Allardet-Servent et al. 1988). Scholz et al. (2008b) confirmed that PCR methods based 
on the 16S rRNA amplified a DNA fragment common to all Brucella species, although cross-
reactions with members of the closely related genus Ochrobactrum were reported. For 
general identification purposes the preferred target is the IS711, as it has a restricted 
occurrence in Brucella and is present in multiple copies resulting in high sensitivity and the 
ability to directly test clinical samples (Halling et al. 1993). The AMOS PCR was developed 
to differentiate between the Brucella species and is based on the insertion site of the IS711 
element resulting in unique profiles for strains of B. melitensis, B. abortus, B. suis and B. 
ovis. In contrast, B. neotomae, B. canis, biovar 4 of B. suis, B. abortus biovar 3 and the 





The PCR has several advantages over traditional microbiological techniques for the 
identification of Brucella species. Firstly, the results are available within a few hours 
compared with several days when conventional microbiological methods are used (Matar et 
al. 1996). Secondly, it can be automated with a subsequent reduction in cost, and only a small 
volume of sample is required (Bricker and Halling 1994). Thirdly, it minimises the need to 
handle potentially infectious samples, as live organisms are not necessary for this test (Matar 
et al. 1996, Bricker and Halling 1994). Finally, contamination with other microbes that might 
be present in tissue samples do not affect the test (Bricker and Halling 1994). However, there 
are some challenges using the PCR in a laboratory including contamination of the DNA, as 
the assay has to be performed under strict standardized conditions which are not always 
available in laboratories (Costa et al. 1996). 
 
2.9.1.3.2 Gamma Interferon Assay (γ IFN) 
 
The gamma interferon test has been developed as an in vitro alternative to the Skin Delayed-
Type Hypersensitivity test (Weynants et al. 1995). The γ IFN involves using a mixture of 
cytoplasmic protein from B. melitensis B115 with whole blood culture as a specific antigenic 
stimulus for cattle. Weynants et al. (1995) confirmed that this test offered the advantage of 
being able to distinguish between false positive and true positive results; however, as with 





2.9.1.3.3 Skin Delayed-Type Hypersensitivity (SDTH) 
 
The SDTH test has been widely used for the diagnosis of brucellosis in ruminants, and it is 
a useful addition to serological tests (Bercovich 2000). The principle of this test is similar to 
the tuberculin test for tuberculosis, and the test evaluates the cell-mediated immunity after 
the intradermal injection of 0.1 ml of brucellin into the caudal tail fold or the skin of the neck 
(Bercovich et al. 1993). Within 24 to 72 hours after injection, a hypersensitivity reaction is 
detectable at the site of injection in diseased animals. The intensity of the reaction is 
determined by the degree of skin swelling and an increase in skinfold thickness of 2 mm or 
more is considered a positive reaction (Bercovich et al. 1993). 
 
Measuring cell-mediated immunity has significant benefits in resolving some of the 
diagnostic dilemmas associated with other serological tests, due to the intracellular nature of 
this bacteria (Bercovich et al. 1989). The SDTH test offers the advantage in being able to 
confirm the status of false negative results from serological tests, and can detect latent 
carriers. Bhongbhibhat et al. (1970) reported that the test could distinguish between 
infections with B. melitensis and B. abortus or B. suis. However, a study undertaken by 
Bercovich (2000) confirmed that the test was unable to distinguish between naturally infected 
and vaccinated animals. Weynants et al. (1995) reported that if the SDTH was repeatedly 
used in an animal then the animal's immune status could change, interfering with subsequent 
serological tests. In a study undertaken by Bercovich (2000) it was suggested that the test 
should not be used in brucellosis-free areas to prevent the confusion of interpreting positive 
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readings and they reported that the benefit of the SDTH was reducing the number of false 
negative results arising from some serological tests. 
 
2.10 Treatment of brucellosis 
 
The treatment of brucellosis in animals is a challenge because of the organism’s intracellular 
nature (Metcalf et al. 1994). However treatment of livestock with brucellosis is rarely 
undertaken because of the expense associated with the treatment, and the priority to eliminate 
infection from the herd or flock (Robinson 2003). Several antibiotics have been used to 
successfully treat brucellosis in livestock, with the commonly used ones being 
oxytetracycline and streptomycin with sulphadiazine (Radwan et al. 1995, Radwan et al. 
1993). However incomplete or inadequate treatment can result in the development of chronic 
infection. In conclusion, treatment of infected animals is not practical or feasible from an 
economic point of view unless the animals have significant value. 
  
In humans two treatment regimens have been recommended: a combination of rifampicin 
and oral doxycycline twice a day over a 6-week course (Al-Tawfiq 2008); or a combination 
of three or four antibiotic drugs such as doxycycline, rifampicin, streptomycin and 
aminoglycoside for a prolonged course (> 45 days). These regimes have been found to 
successfully treat disease in humans (Ariza et al. 2007, Corbel et al. 2006). Ariza et al. (2007) 
found that using a combination of at least two antibiotics such as streptomycin, rifampin, 
doxycycline or trimethoprim-sulfamethoxazole improved the efficacy of treatment in 
humans, although they must be used for prolonged periods. Tetracyclines are generally 
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contraindicated for pregnant patients and children <8 years old. Rifampicin 900mg once daily 
for 6 weeks is considered the drug of choice for treating brucellosis in pregnant women. In 
children <8 years old the preferred regimen is rifampicin with cotrimoxazole (trimethoprim-
sulfamethoxazole) for 45 days. An alternative regimen consists of a combination of 
rifampicin for 45 days with gentamicin 5 to 6 mg/kg/day for the first 5 days (Solera et al. 
1997). Historically, 2% of humans infected with B. melitensis and who aren’t treated will die 
from endocarditis or meningitis (Ko and Splitter 2003, Madkour 2001b). Although all 
patients will have some response to antibiotic treatment, clinical symptoms may last for 
weeks or months, although most patients recover within a year (Bossi et al. 2004). The World 
Health Organization (WHO) recommended antibiotic treatment for humans is 100 mg 
doxycycline twice daily for six weeks combined with either 600 to 900 mg of rifampicin 
daily for six weeks, or 1 g of streptomycin once daily for 2 to 3 weeks (Ariza et al. 2007). 
Treatment of humans with brucellosis is costly and time consuming, and often requires long 
periods of hospitalisation (Del Pozo and Solera 2012). 
 
2.11 Prevention and control of brucellosis 
 
Vaccination is a key component of disease control and, as outlined previously, a range of 
vaccines are available for the control of the disease, although only B. melitensis Rev-1 
vaccine has been shown to be effective in preventing brucellosis in small ruminants (sheep 
and goats) (Blasco 1997). The disadvantage of vaccination is the induction of antibodies 
which can potentially interfere with the interpretation of results from diagnostic tests; 
however the advantages of vaccination far outweigh this disadvantage (Blasco 1997). When 
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administered by the classic subcutaneous route, a long-lasting serological response is 
induced, which makes an eradication program based on test and slaughter impractical. When 
the same vaccine is administered by the conjunctival route, the immunity conferred is similar 
to that induced by the subcutaneous route, although the serological response is significantly 
reduced, making it suitable for use in an eradication program (Corbel et al. 2006, Blasco 
1997). Many vaccines have been produced to protect sheep, goats, cattle and pigs from 
Brucella infection. However, the most common vaccine to control B. melitensis is Rev-1 
vaccine, with S19 and RB51 commonly being used to control B. abortus infection in endemic 
areas. There are three different strategies for controlling brucellosis: vaccination of the entire 
at-risk population (mass vaccination); vaccination of young animals and removal of infected 
animals; and test and slaughter (McDermott and Arimi 2002). In many high-income 
countries, brucellosis has been successfully controlled or eliminated in livestock populations 
through a range of strategies (McDermott et al. 2013). The advantages and disadvantages of 
these are summarised in Table 2.6 and in the following sections. 
 
2.11.1 Test and slaughter of infected animals  
 
Whole flock/herd testing and removal of infected animals is usually the most efficient 
method for the rapid elimination of an introduced exotic disease, such as brucellosis or other 
emergency diseases. It is also often the most cost-effective, although it can still be very 
expensive and requires the availability of accurate diagnostic test(s) (Corbel et al. 2006) and 
significant infrastructure for the safe disposal of the positive animals. As the remaining 
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animals do not have protective antibody there is the potential for an outbreak if disease is 
reintroduced to the population (Smits 2013). 
 
Table 2.6: Summary of the advantages of brucellosis control strategies 
Strategy   Advantages Disadvantages 
Mass vaccination  Lower cost Abortions post vaccination 
Easy to implement and 
manage 
Potential public health hazards 
from the process of vaccination 
Herd/flock immunity quickly 
established and maintained by 
vaccinating young animals 
Difficulty in distinguishing 
between vaccinated and infected 
animals 
Well accepted by owners Infected animals remain on the 
farms 
Vaccination of 
young animals & 
elimination of 
infected animals 
Minimises vaccine induced 
abortions 
Herd/flock immunity established 
slowly 
Test and slaughter 
of infected animals 
If successful, will lead to 
elimination of infected 
animals 
Requires an efficient and very 
well-organised veterinary service 
Diagnostic tests are more 
accurate in non-vaccinated 
animals but still not optimum 
Suitable for low disease 
prevalence areas only 
Cost is very high & may 
require whole herd/flock 
culling to be effective but the 
most efficient method for the 
rapid elimination of the 
disease 
Risk of subsequent epidemics in 
animals & human infection (the 





2.11.2 Brucella vaccines 
 
Vaccination has been an important step in controlling brucellosis in many countries, regions 
and individual herds (Schurig et al. 2002). Routine and sustained vaccination has been shown 
to result in a significant decrease in the disease’s prevalence with time (Godfroid et al. 2011, 
Blasco 1997). However, Alton et al. (1980) highlighted that the cessation of vaccination 
could result in a susceptible cattle population and other measures were also needed to 
minimise the likelihood of reintroduction of the bacterium. There have been numerous 
vaccines used for controlling brucellosis in different species; however, many of them have 
been discarded due to the low level of immunity induced.  
 
Nicoletti (2010) reported that live attenuated vaccines were the most effective vaccines and 
several studies have been undertaken to determine the most effective dose and route of 
administration of different vaccines. The routes trialled have included intradermal, 
subcutaneous (SC), oral, conjunctival, intra-vaginal, intra-caudal and intrauterine (Nicoletti 
1990). The most commonly used and practical route is SC, however the conjunctival route 
is also used widely, although the serological response after vaccination with Rev-1 via this 
route in rams has been shown to be of a lower intensity and a shorter duration than that 




2.11.2.1 Live Brucella Vaccines 
2.11.2.1.1 Vaccines for small ruminants 
 
The most widely used vaccine for the prevention of brucellosis in sheep and goats is B. 
melitensis Rev-1 (Blasco 1997). It was developed in the 1950’s and is a live attenuated strain 
of virulent B. melitensis which is dependent upon the presence of streptomycin for growth 
(Herzberg and Elberg 1955). The vaccine is efficacious in adult animals, as well as lambs 
and kids, and induces a high and durable immune response (Blasco 1997, Alton and Elberg 
1967).  
 
The vaccine can be administered via the conjunctival or subcutaneous route in both adult and 
young animals. In young animals, vaccination via the conjunctival route confers adequate 
protection without interfering with serological assays (Blasco 1997). Although the vaccine 
is usually given to kids and lambs between the ages of 3 to 6 months via a subcutaneous or 
conjunctival injection; Blasco (1997) recommended that in eradication programmes this 
vaccine should not be administered by this route as it results in a high level of interference 
with serological tests. When the vaccine is administered by the conjunctival route, protection 
is induced without the issue of persistent antibody levels. Use of the Rev-1 vaccine in whole-
flock vaccination programmes has been considered the only practical method to control 
infection with B. melitensis in small ruminants in areas with low socio-economic levels, 
extensive management systems or where there is a high prevalence of infection (Montiel et 




There is no entirely safe strategy for mass vaccination because of the risk of abortion in 
pregnant animals; therefore it is recommended that Rev-1 should not be used in animals that 
are over half way through their gestation, as this is the critical period for abortions (Gonzalez 
et al. 2008). There are also other disadvantages of this vaccine including the bacteria’s 
potential to develop resistance to streptomycin which is used to treat infection with B. 
melitensis in humans. Furthermore Rev-1 has the potential to infect humans, and 
consequently its use as a vaccine for humans is not recommended (Blasco and Diaz 1993).   
 
2.11.2.1.2 Vaccines for other animal species 
 
Brucella abortus strain 19 (S19) has been the most widely used vaccine to prevent bovine 
brucellosis (Nicoletti 1990) and it is considered the reference vaccine to which other vaccines 
are compared against (Nicoletti 1990). This strain was isolated in 1923 from a bovine milk 
sample and then sub-cultured 19 times (Nicoletti 1990). The effectiveness of S19 is 
influenced by a range of factors, including the route of administration, the age of the 
vaccinated animals, the prevalence of infection in the herd and the dose (number of bacteria) 
administered (Arenas-Gamboa et al. 2009, Schurig et al. 2002, Nicoletti 1990). Vaccinating 
calves with S19 prevents infection through an increased production of antibodies to the O 
antigens of LPS (Nicoletti 1990). According to Sangari et al. (1996) and Jones et al. (1965) 
S19 is unable to grow in the presence of erythritol, is less virulent than field strains, has high 




Many studies have investigated the dose required through different routes, and it is 
recommended that 11.5 x1010 cfu/dose are administered subcutaneously in heavily infected 
areas. Although more protection can be offered through the conjunctival route, this method 
is usually not practical in field situations (Fensterbank and Plommet 1979). Fensterbank and 
Plommet (1979) reported that two vaccinations with 5 x 1010 cfu/dose by the conjunctival 
route would be more economical, effective and without risk of inducing a serological 
response as well as offering the advantage that vaccination could be performed at any age, 
however this is not practical in most grazing herds. 
 
The RB51 strain of B. abortus is a laboratory-derived O antigen deficient mutant of a virulent 
strain of B. abortus (S2308) (Schurig et al. 1991). This vaccine was developed to overcome 
the problems of S19 and has been used in several countries to protect against bovine 
brucellosis (Schurig et al. 2002). The advantages of this vaccine is that abortions are rarely 
induced by administering the vaccine and higher levels of protection against infection with 
B. abortus are induced, compared with S19 (Palmer et al. 1996). Furthermore the immunity 
induced in cattle is mostly cellular, leading to fewer false positive reactions on serological 
testing (Stevens and Olsen 1996). However, the organism has been detected in the milk of 
vaccinated cows, it is not effective against B. melitensis in sheep, and it can produce infection 
in humans (Moriyón et al. 2004). 
 
Brucella suis S2 vaccine is a live attenuated brucellosis vaccine that was developed in China 
(Avila-Calderón et al. 2013). This vaccine has the advantage that it can be administered 
orally, as well as via subcutaneous injection to pigs, cattle, sheep and goats (Xin 1986). It 
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can initiate strong protection in pigs exposed to wild B. suis and has the advantage that it can 
be used in different domestic animal species (Xin 1986). 
 
2.11.2.2. Killed Brucella vaccines 
2.11.2.2.1 Brucella melitensis H38 
 
Brucella melitensis H38 killed vaccine has been shown to induce effective immunity against 
challenge with B. abortus (Gonzalez et al. 2008). This vaccine contains a suspension of 
formalin-killed cells at a concentration of 15 x 1010 cells/ml in incomplete adjuvant (Renoux 
and Renoux 1973). However, Meyer and Gibbons (1978) reported that the vaccine induced 
high, persistent titres and caused long-lasting unacceptable local reactions at the injection 
site. 
 
2.11.2.2.2 Brucella abortus strain 45/20 vaccine 
 
This vaccine is not widely used because it may result in a reaction (lesion) developing at the 
injection site, it can cause abortions in vaccinated cattle if the organism reverts to a smooth 
form (Schurig et al. 2002, Hall et al. 1976) and non-agglutinating immunoglobulins (IgG) 
can act as blocking antibodies, delaying bacterial clearance and increasing the likelihood of 
chronic infections (Stevens and Olsen 1996, Parma et al. 1987). However, this vaccine does 




2.11.2.3 Vaccines against brucellosis in humans 
 
The 19-BA vaccine is a derivative from B. abortus S19 from which dissociated colonies were 
selected and cultured. In 1945, Dr Pelagea Vershilova from the Gamaleya Research Institute 
for Epidemiology and Microbiology in Moscow was able to select a sub-clone of В. abortus 
S19, which possessed both minimal reactogenicity and high immunogenic properties for 
humans (Feodorova et al. 2014, Sumarokov et al. 1984, Vershilova et al. 1982). The vaccine 
was first trialled in human volunteers in 1946 and 5,000 at risk workers were vaccinated 
(Feodorova et al. 2014). It was considered that 2.5–8.0 x 108 organisms was a safe dose to 
induce an immunological protective response when administered via the subcutaneous route. 
The Epidemic Control Services of the former USSR subsequently used this vaccine in 
humans as a primary prophylactic measure against the disease (Aleksandrov et al. 1961). 
 
The B. abortus 104 M vaccine has also been used in the former USSR and in China to control 
and prevent B. abortus infection in humans (Deqiu et al. 2002). The T and M strains of 
vaccine were isolated from the foetus of an aborted calf in 1950 by a Russian scientist and 
tests indicated that the M strain had low virulence, high stability and high immuno-
antigenicity. A skin scratch vaccination method was used to introduce 5 x 109 bacteria and 
achieved 90% protection with 12 months duration. This vaccine has been used in humans 
since 1965 (Deqiu et al. 2002). 
 
WR201 is a live attenuated purine auxotroph, which has experimentally been shown to 
protect mice against infection with virulent B. melitensis 16M. Protection is related to the 
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production of IFN-γ by antigen-stimulated immune spleen cells and production of anti- LPS 
antibodies (Hoover et al. 1999). Izadjoo et al. (2004) suggested that induction of purine 
auxotrophy in B. melitensis has the potential to develop into a convenient, safe and efficient 
human vaccine and they recommended that further work should be undertaken on this as a 
potential vaccine candidate against brucellosis in humans. 
 
2.11.3 Other preventive measures 
 
Brucellosis is usually introduced into a flock/herd through contact with infected animals 
and/or semen of infected males. To prevent its introduction new animals should be purchased 
from Brucella-free herds and new animals should be isolated and screened before they are 
added to the herd. However managing the disease in endemic areas where animals co-graze 
can be difficult unless a vaccination programme is also implemented (Al-Rawahi 2015). 
Improvements in: awareness about brucellosis; movement restrictions; diagnostic 
capabilities; and surveillance of the disease in livestock, humans and wildlife are beneficial 
in the effective control of the disease (Corbel et al. 2006). In order to increase awareness 
among the farmers it is important to conduct public education programmes on the clinical 
signs and transmission routes of the diseases and methods to prevent and control its 
introduction and spread (Chen et al. 2016). In addition, other biosecurity measures that could 
help to reduce transmission include: isolating flocks on common grazing land and avoiding 
shared watering points; developing a strong quarantine and border control system; disposing 
of placenta, and non-viable birth tissue by incineration or deep burial; using personal 
protective equipment (wearing protective glasses and gloves) when milking ruminants and 
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when assisting livestock giving birth; and boiling or heating milk before consumption or 
using it to prepare other dairy products (Islam et al. 2013).  
 
Understanding the epidemiology of brucellosis in a country, in particular the distribution of 
the disease, risk factors for infection and the disease’s impact on local communities are key 
components of the local prevention and control of the disease. In the following chapter the 
results of a cross-sectional study are presented to highlight the distribution of brucellosis in 





Serological Survey of Brucellosis in Sheep and Goats in the Iraqi 
Kurdistan Region 
3.1 Introduction  
 
Brucellosis is an infectious bacterial disease of worldwide importance in livestock and people 
(Hadush and Pal 2013). The disease is widespread, particularly in some Mediterranean and 
Middle East countries (Abo-Shadi et al. 2014), however a thorough study on the 
seroprevalence in animals has not previously been undertaken in the Iraqi Kurdistan Region. 
A cross-sectional serological study was undertaken to better understand the distribution and 
frequency of brucellosis in sheep and goats in this region and the results of this study, in 
particular the disease’s seroprevalence, are reported in this chapter.  
     
3.2 Materials and Methods 
3.2.1 Study population and sampling 
 
A cross-sectional study was conducted in the Iraqi Kurdistan Region to determine the 
seroprevalence of brucellosis in sheep and goats. Field sampling was carried out from March 
to May 2015 throughout the Iraqi Kurdistan Region using two different sampling plans. The 
sample size was calculated in the program EpiTools (Sergeant 2017) using a test sensitivity 
of 92% and a test specificity of 99%  (Rahman et al. 2013a, Blasco et al. 1994), to be 95% 
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confident of estimating an expected prevalence of 10% with a precision of 2%. In Sulaymani 
and Dohuk Provinces a multi-stage sampling protocol was adopted. Six districts were 
randomly selected from the 22 districts in Sulaymani Province and two were similarly 
randomly selected from the six districts in Dohuk Province for sampling. Within each 
selected district one sub-district was randomly selected. Two villages were then randomly 
selected from each selected sub-district and within each village five farmers were randomly 
selected from those who owned at least 50 sheep and/or goats. Finally, five animals (sheep 
and/or goats) were randomly selected from the selected farmers with the first animal being 
selected randomly and then every 10th animal was selected when the animals were run 
through an open gateway. In total 300 blood samples (216 sheep and 84 goats) were collected 
(6 districts × 1 sub-district × 2 villages × 5 farmers × 5 animals = 300 samples) from 
Sulaymani Province and 100 blood samples (82 sheep and 18 goats) were randomly collected 
from Dohuk Province (2 districts × 1 sub-district × 2 villages × 5 farmers × 5 animals = 100 
samples). The number of sheep and goats sampled in the provinces (Table 3.1) was in 
proportion to the number of animals in that province. 
 
In Erbil and Kirkuk Provinces, blood samples were collected from sheep and goats by 
cooperating with the Veterinary Medical Centres (VMC) in these provinces. In Erbil 
Province there are 27 VMCs in 10 districts, of which 18 agreed to participate and collected 
25 blood samples each from sheep and goats (total 450 blood samples - 236 sheep and 214 
goats). In Kirkuk Province eight of 13 VMCs in 4 districts agreed to participate and collected 
25 samples each for a total of 200 blood samples from 40 flocks (160 sheep and 40 goats). 
The two different sampling methodologies used in this study are summarised in Figure 3.1. 
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A total of 694 blood samples were collected from 137 flocks containing sheep (flocks either 
only contained sheep or both sheep and goats) and 356 samples from 113 flocks containing 
goats (flocks either contained only goats or contained both sheep and goats). In total, 1,050 
blood samples from sheep and goats were collected from 166 flocks in the four sampled 
provinces. Five ml of blood was collected from the jugular vein directly into vacutainer tubes 
from each animal. All sampling had been approved by the Animal Ethics Committee of 
Murdoch University - R2698/14. After collection, blood samples were transported to one of 
four laboratories (Erbil Veterinary Hospital, Kirkuk Veterinary Hospital, University of 
Sulaymani and Semel Veterinary Hospital), where they were centrifuged at 4,000 rpm for 5 
minutes, after which the sera was separated and stored in Eppendorf Tubes prior to testing. 
 
In the first phase of testing all samples were tested within 24 hours of collection with the 
RBT at room temperature and the results interpreted within 2 to 4 minutes of mixing, as per 
the manufacturer’s recommendations (Figure 3.2). In the second phase of testing, the 65 
positive samples on the RBT and an equal number of randomly selected negative samples 
(to see if there are any false negative samples) collected from animals located in the same 
villages as the test-positive animals were tested with an enzyme-linked immunosorbent assay 
(ELISA) (Nova Tec Immundiagnostica GmbH Technologie & Walpark/Germany 
www.novaTec-ID.com) to confirm their brucellosis status. An animal was classified as 
seropositive if it tested positive to both the RBT and the ELISA (tests interpreted in series). 
Positive and negative controls were used in both the RBT and ELISA tests to confirm that 
the tests were working. The real prevalence (RP) was estimated using the formula:  










Figure 3.2: Positive and negative results of the Rose Bengal Test 
Number 4 is a positive result and numbers 1, 2, 3, 5 and 6 are negative results 
 
Table 3.1: Distribution of samples (sheep & goats) collected for the study on the 
seroprevalence of brucellosis in the Provinces of Kurdistan, and percentages in each 
province. 
Province  Animal  Number of males 
tested (%) 
Number of 
females tested (%) 
Total number tested 
(%)* 
Erbil 
Sheep  81 (11.7) 155 (22.3) 236 (34.0) 
Goats  47 (13.2) 167 (46.9) 214 (60.1) 
Sulaymani 
Sheep 59 (8.5) 157 (22.6) 216 (31.1) 
Goats 13 (3.7) 71 (19.9) 84 (23.6) 
Kirkuk 
Sheep 29 (4.2) 131 (18.9) 160 (23.1) 
Goats 11 (3.1) 29 (8.1) 40 (11.2) 
Dohuk 
Sheep 46 (6.6) 36 (5.2) 82 (11.8) 
Goats 7 (2.0) 11 (3.1) 18 (5.1) 
Total 
Sheep 215 (31.0) 479 (69.0) 694 (100) 
Goats 78 (21.9) 278 (78.1) 356 (100) 




3.2.2 Data management and analysis 
 
Data were entered into a Microsoft Excel spreadsheet and analysed in Excel and SPSS (IBM 
SPSS Statistics 24 for Windows®, IBM Corporation, Route 100 Somers, New York, USA).  
Descriptive statistics were calculated for each variable of interest (species, sex, provinces, 
age and flock type). Odds ratios and their 95%CI were calculated using Woolf's method 
(Kahn and Sempos 1989). The Fisher’s exact test and chi-square test for independence were 
also used to determine statistical associations. The real and test prevalence were calculated 
and their 95%CI estimated using Ross’s method (Ross 2003). 
 
3.3 Results  
3.3.1 Seroprevalence of brucellosis in sheep and goats  
 
Sixty five of the 1,050 (6.2%) samples were RBT test-positive (51 sheep & 14 goats) (95%CI 
4.8 - 7.8). Of the 130 samples tested with both the RBT and ELISA, 51 (39 sheep and 12 
goats) were positive to both tests (overall seroprevalence of 4.9%; 95%CI 3.6 - 6.3). Fourteen 
samples (12 sheep and 2 goats) were positive on the RBT and negative on the ELISA test; 
three samples (2 sheep and 1 goat) were negative on the RBT but positive on the ELISA test; 




The test seroprevalence in sheep (5.6%; 95%CI 4.0 - 7.6) was similar to that in goats (3.4%; 
95%CI 1.8 - 5.8) (OR 1.67: 95%CI 0.86 - 3.22) (Table 3.2). After adjusting for the sensitivity 
and specificity of the tests, the overall real prevalence was estimated at 5.8% (95%CI 4.5 - 
7.4). 
 
Table 3.2: Seroprevalence to brucellosis based on seropositivity to both the Rose Bengal test 

















Sheep 39 655 
5.62% 
(4.0 - 7.6) 
6.72% 
(5.0 - 8.8) 
1.67 
(0.86 - 3.22) 
Goats 12 344 
3.37% 
(1.8 - 5.8) 
4.02% 
(2.2 - 6.6) 
1.0 
Total 51 999 
4.86% 
(3.6 - 6.3) 
5.81% 
(4.5 - 7.4) 
- 
  
3.3.2 Gender specific seroprevalence for brucellosis  
 
Overall 757 female animals were sampled in this study, representing 72.1% of the sample 
population. For sheep, 69% (479) were females and 31% (215) males, whilst for goats 78.1% 
(278) were females and 21.9% (78) were males. The test seroprevalence in female sheep 
(5.2%; 95%CI 3.4 - 7.6) was similar to that of male sheep (6.5%; 95%CI 3.6 - 10.7) (OR 
0.79; 95%CI 0.40 - 1.55) (Table 3.3). Similarly, for goats the test seroprevalence in females 
(4.0%; 95%CI 2.0 - 7.0) was not significantly different to that of males (1.3%; 95%CI 0.03 
- 6.9) (OR 3.17; 95%CI 0.40 - 24.96) (Table 3.3). 
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Table 3.3: Seroprevalence to brucellosis (positive on both RBT & ELISA Tests) in male 
and female sheep and goats.  











Odds ratios    
(95%CI) 
Sheep 
Female 25 454 5.2% (3.4 - 7.6) 0.79 (0.40 - 1.55) 
Male 14 201 6.5% (3.6 - 10.7)  
Goats 
Female 11 267 4.0% (2.0 - 7.0) 3.17 (0.40 - 24.96) 
Male 1 77 1.3% (0.0 - 6.9)  
Total 
Female 36 721 4.8% (3.4 - 6.5) 0.93 (0.50 - 1.72) 
Male 15 278 5.1% (2.9 - 8.3)  
 
 
3.3.3 Seroprevalence to brucellosis in sheep and goats from different 
provinces 
 
There was no overall significant difference (P = 0.76) in the test seroprevalence in sheep 
between provinces based on the RBT and ELISA results interpreted in series (Table 3.4). 
The test seroprevalence was highest in sheep from Erbil (6.8%) and lowest in Kirkuk (4.4%). 
Similarly, there was no significant difference in the test seroprevalence in goats between 
provinces (P = 0.56) (Table 3.4). For goats the test seroprevalence was highest in Sulaymani 




Table 3.4: Seroprevalence of brucellosis (based on positivity to both the RBT & ELISA) 
and comparisons between different provinces of Kurdistan. 
Species Province Number 
positive on 












Sulaymani 12 204 
5.6% 
(2.9 - 9.5) 
0.81 
(0.37 - 1.75) 
Kirkuk 7 153 
4.4% 
(1.8 - 8.8) 
0.63 
(0.25 - 1.57) 
Dohuk 4 78 
4.9% 
(1.3 - 12.0) 
0.71 
(0.23 - 2.17) 
Erbil* 16 220 
6.8% 
(3.9 - 10.8) 
 
Goats 
Sulaymani 5 79 
6.0% 
(2.0 - 13.3) 
1.87 
(0.58 - 6.07) 
Kirkuk 0 40 
0.0% 
(0.0 - 8.8) 
- 
Dohuk 0 18 
0.0% 
(0.0 - 18.5) 
- 
Erbil* 7 207 
3.3% 
(1.3 - 6.6) 
 
* Erbil is the comparison province. 
 
3.3.4 Seroprevalence of brucellosis in different age groups   
 
The test seroprevalence in sheep ≤ 6 months (4.1%) was similar to that of sheep older than 6 
months of age (5.7%) (OR 0.70; 95%CI 0.16 - 3.0) (Table 3.5). No test seropositive goats ≤ 
6 months were detected compared to 3.5% of goats older than 6 months of age (P = 0.55) 
(Table 3.5).  
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Table 3.5: The influence of age on test seroprevalence in the sampled animals.     















≤ 6 months 2 47 
4.1% 
(0.5 - 14.0) 
0.70 
(0.16 - 3.0) 
> 6 months 37 608 
5.7% 
(4.1 - 7.8) 
1.0 
Total 39 655 
5.6% 
(4.0 - 7.6) 
- 
Goats 
≤ 6 months 0 17 
0.0% 
(0.0 - 19.5) 
P = 0.55* 
> 6 months 12 327 
3.5% 
(1.8 - 6.1) 
Total 12 344 
3.4% 
(1.8 - 5.8) 
- 
* Results from Fisher’s exact test 
 
The association between demographic factors and seropositivity are summarised in Table 
3.6. Univariable analyses for the seroprevalence of individual animals revealed that overall 
older animals (> 6 months of age) had a slightly higher seroprevalence (5.0%) than lambs 
and/or kids aged ≤ 6 months (3.0%) (OR 1.68; 95%CI 0.40 - 7.1) and no seropositive sheep 
or goats ≤ 6 months were detected in flocks containing sheep only or goats only. The overall 
seroprevalence in female animals (sheep and goats) (4.8%) was similar to that of males 
(5.1%) (OR 0.93; 95%CI 0.50- 1.7). Similarly, the seroprevalence in female animals in mixed 
flocks (containing sheep and goats) (5.4%) was not different to that of males (7.1%) (OR 




Table 3.6: Influence of flock composition on animal level seroprevalence 
Flock type        Variable Seropositive animals Odds ratio 
(95%CI) 
P value 
 Yes (%) No (%) 
Sheep only 
Female 10 (4.3) 222 (95.7) 1.22 (0.37 - 4.0) 0.499* 
Male 4 (3.6) 108 (96.4) 1.0 
Goats only 
Female 4 (3.4) 115 (96.6) 1.36 (0.15 - 12.5) 0.630* 
Male 1 (2.5) 39 (97.5) 1.0 
Mixed sheep 
and goats flock 
Female 22 (5.4) 384 (94.6) 0.75 (0.15 - 1.6) 0.233 
Male 10 (7.1) 131 (92.9) 1.0 
Total 
Female 36 (4.8) 721 (95.2) 0.93 (0.50 - 1.7) 0.403 
Male 15 (5.1) 278 (94.9) 1.0 
Sheep only 
> 6 months 14 (5.1) 260 (94.9) - 0.286* 
≤ 6 months 0 (0.0) 25 (100.0) - 
Goats only 
> 6 months 4 (2.8) 137 (97.2) - 0.869* 
≤ 6 months 0 (0.0) 5 (100.0) - 
Mixed sheep 
and goats flock 
> 6 months 31 (5.4) 538 (94.6) 0.98 (0.22 - 4.3) 0.599* 
≤ 6 months 2 (5.6) 34 (94.4) 1.0 
Total  
> 6 months 49 (5.0) 935 (95.0) 1.68 (0.40 - 7.1) 0.364* 
≤ 6 months 2 (3.0) 64 (97.0) 1.0 
* Results of analysis with a Fisher’s exact test 
 
3.3.5 Flock based seroprevalence of brucellosis 
 
Overall 18.7% (95%CI 13.1 - 25.4) of flocks contained at least one animal that was positive 
to both the RBT and ELISA tests. The lowest flock test prevalence was in flocks only 
containing goats (6.9%; 95%CI 0.8 - 22.8). In contrast, 16.7% (95%CI 7.9 - 29.3) of flocks 
only comprising sheep contained at least one test positive sheep. The highest flock test 
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prevalence (24.1%; 95%CI 15.4 - 34.7) was in flocks containing both sheep and goats (Table 
3.7).  
 
Table 3.7: Flock level seroprevalence in sampled flocks.    
Flock type Number of flocks 












Sheep only  9 54 
16.7% 
(7.9 - 29.3) 
0.63 
(0.26 - 1.51) 
Goats only  2 29 
6.9% 
(0.8 - 22.8) 
0.23 






(15.4 - 34.7) 
1.0 
Total 31 166 
18.7% 






In this study 4.9% of animals were classified as test seropositive (positive to both the RBT 
and ELISA tests). This was lower than the 14.5% reported by Jabary and Al-Samarraee 
(2015) in unvaccinated flocks in Sulaymani, based on the RBT alone, and that reported by 
Al-Naqshabendy et al. (2014) of 39.1% in non-vaccinated ewes in Dohuk, using the ELISA 
test. The differences in the results between the current survey and previous surveys may be 
the result of ongoing vaccination control programs of lamb and kids from 3 to 6 months of 
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age in the Kurdistan region (MAWR 2015). In contrast, the test seroprevalence observed in 
this study in sheep (5.6%; 95%CI 4.0 - 7.6) was higher than the 2.2% (95%CI 0.5 - 3.5) 
reported in a study of sheep (using the RBT and ELISA tests in series) in Northern Jordan 
(Al-Talafhah et al. 2003). Also the test seroprevalence in sheep was higher than a study 
(4.2%; 95%CI 2.9 - 5.9) in Sarab City (East Azarbayjan province) in Iran (Akbarmehr and 
Ghiyamirad 2011). These differences were not unexpected given differences in husbandry 
and management practices between countries. 
 
In the current study the test seroprevalence in sheep (5.6%; 95%CI 4.0 - 7.6%) was similar 
to that in goats (3.4%; 95%CI 1.8 - 5.8%) (OR: 1.71, 95%CI 0.88 - 3.3). This similarity is 
not unexpected given the similar traditional husbandry practices for handling both species. 
Hosie et al. (1985) in Yemen also reported a similar test seroprevalence in sheep and goats 
(0.6%, 95%CI 0.2 - 1.5; and 0.4% 95%CI 0.1 - 1.4, respectively). However, it is likely that 
the differences in the prevalence between studies arose because of different management and 
husbandry practices adopted as outlined earlier, although the method of selecting animals 
could also account for these differences. 
 
In this study there was no significant difference in the animal-level test seroprevalence 
between provinces. Again this was not unexpected due to the similar management and 
husbandry systems adopted between provinces. However, surprisingly no seropositive goats 
were found in Kirkuk and Dohuk Provinces. This could be due to the sample size, as the 
number of sheep and goats sampled in Erbil and Sulaymani provinces was larger than that 
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for Kirkuk and Dohuk (the probability of not getting a positive goats in Kirkuk and Dohuk 
provinces were 25.38 and 53.39%, respectively). 
 
The test seroprevalence in males and females was also similar in the current study for both 
sheep and goats. This finding was again expected because of the similar management 
practices male and female sheep and goats are subjected to. These findings concur with those 
previously obtained by Jabary and Al-Samarraee (2015) who reported a test prevalence of 
14.3 and 10.1% in female and male small ruminants (sheep and goats), respectively in 
Sulaymani and the study of Al-Hankawe and Rhaymah (2012) who reported a test prevalence 
(ELISA) of 16.1 and 15.2% in females and males, respectively in  Nineveh province. 
 
In the current study the seroprevalence increased with age, although not significantly. This 
rise is most likely due to the increased number of contacts between animals increasing the 
likelihood of contact with an infected animal, as well as mating after puberty resulting in a 
greater chance of infection, as has been described by others (Zeng et al. 2017, Teklue et al. 
2013, Dinka and Chala 2009).   
 
Almost one-fifth (18.7%) of the flocks tested in this study contained one or more animals 
test positive for brucellosis. A higher, although not significant, proportion of flocks 
comprising both sheep and goats contained at least one seropositive animal (24.1%) 
compared with flocks that only contained sheep (16.7%). Generally in Iraq, small ruminants 
(sheep and goats) are usually run as one large flock. Other studies conducted in the region 
prior to this study have unfortunately not separated out the test prevalence for the two species 
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for comparative purposes so it was not possible to compare the results of the current study 
with other local studies.  
 
Differences in test seroprevalence between studies can arise from: the sample size; the tests 
used; the method of interpreting seropositivity ie tests interpreted in series or in parallel; the 
study location; the associated management and husbandry practices adopted within those 
locations; and the control methods adopted (biosecurity measures and vaccination)  
(Haileselassie et al. 2011). Further research is needed on the incidence, the Brucella species 
affecting small ruminants, risk factors for infection, and manifestations of brucellosis in other 
regions of Iraq, as well as in Kurdistan. Control or elimination of risk factors for disease will 






Questionnaire Survey of Farmers in the Kurdistan Region: 
Husbandry Practices Adopted and Risk Factors for Brucellosis 
in Sheep and Goats 
4.1 Introduction  
  
Throughout the Middle East, the main Brucella species affecting sheep and goats is B. 
melitensis (Seleem 2010, Pappas and Memish 2007). Brucellosis has been an endemic 
disease in livestock in the Kurdistan Region of Iraq, probably at least since the time of the 
Ottoman Empire in the 1800’s (Obi et al. 2000). Brucellosis can have a considerable impact 
on the economy through direct and indirect effects on livestock production and productivity 
and the associated human-health effects (Al-Majali et al. 2009, Perry and Grace 2009). 
Prevention of brucellosis in humans is dependent upon control of the disease in animals, 
however brucellosis in the Iraqi Kurdistan Region is a widely spread disease and remains a 
challenging public health problem (Jaff 2016), and as with other regions continues to be a 
significant disease impacting livestock productivity (Roth et al. 2003).  
 
The factors influencing the epidemiology of brucellosis in livestock can be divided into those 
associated with the transmission of the disease between flocks and those influencing the 
maintenance and spread of infection within individual flocks (Crawford et al. 1990). The 
demographics and distribution of livestock, management and husbandry systems adopted and 
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environmental factors are all important determinants of disease spread (Al-Majali et al. 2009, 
Salman and Meyer 1984). Understanding these factors is critical for the control and 
eradication of brucellosis. However there is a lack of baseline quality epidemiological data 
on the occurrence and impact of many zoonotic infections, including brucellosis (McDermott 
and Arimi 2002), in the Kurdistan Region of Iraq. Consequently the research outlined in this 
chapter was designed to investigate the role of potential risk factors that could affect the 
seroprevalence of brucellosis in sheep and goats in the Kurdistan Region. The information 
arising from this study will help to improve our understanding of the epidemiology of 
brucellosis, particularly the flock-level factors that are associated with seropositivity. These 
findings can be used to help develop an evidence-based brucellosis control strategy in 
livestock in Kurdistan, as well as other regions of Iraq. 
 
4.2 Materials and methods 
4.2.1 Questionnaire design 
 
At the time of blood sampling (Chapter 3) data on the sampled animals were collected (age, 
gender and species). After blood samples were collected from the selected flocks a 
questionnaire was administered in a face-to-face setting with the owners/managers of the 
sampled livestock to identify risk factors associated with flock-seropositivity. Owners or 
managers of 146 (79 farms owned both goats and sheep, 24 owned goats only and 43 owned 
sheep only) of the 166 sampled flocks were available for surveying (Table 4.1) (20 
owners/managers were not available for surveying when the questionnaire was 
administered). The questionnaire (Appendix 1) included both closed and open questions and 
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was developed in English and then translated into Kurdish, the local language, prior to 
administering to farmers. This questionnaire was designed to collect information from the 
farm owner/manager on their flock including its location, animal species kept and their sex, 
age, and type and flock size, management and husbandry practices adopted (grazing 
practices, methods for disposing afterbirth, source of stock-water, sale and purchase of 
animals, and vaccination history), and incidence of abortions. This questionnaire and study 
was approved by the Human Research Ethics Committee of Murdoch University (approval 
number 2014/190) and was sponsored by the Ministry of Higher Education and Scientific 
Research in Kurdistan Regional Government of Iraq. 
 
Table 4.1: Number of flocks sampled and farmers surveyed in the Kurdistan Region.  
Province Number of flocks 
blood sampled 
(Chapter 3) 




Erbil 86 70 81.4 
Sulaymani 30 28 93.3 
Kirkuk 40 38 95.0 
Dohuk 10 10 100.0 





4.2.2 Statistical Analyses  
 
Data on the individual animal and flock seropositivity (Chapter 3) and results from the 
questionnaires were entered into an Excel spreadsheet and analysed using SPSS (IBM SPSS 
Statistics 24 for Windows®, IBM Corporation, Route 100 Somers, New York, USA). A 
farm/flock was classified as positive if at least one animal (sheep and/or goat) was positive 
to both the RBT and ELISA tests out of the 5 animals sampled from that farm. The analyses 
were conducted in two stages. Firstly, univariable analyses were performed to quantify the 
strength of association between the exposure variables and flock Brucella seropositivity. The 
Chi-square test for independence or the Fisher’s exact test were used to determine if the flock 
seroprevalence was influenced by different husbandry or management practices. Odds ratios 
(OR) and their 95% confidence intervals (95%CI) were also calculated to determine the 
association between factors and seropositivity to brucellosis. In the second stage of the 
analyses, factors in the univariable analyses with a p-value ≤ 0.25 were offered to a 
multivariable logistic regression model. A backward stepwise (conditional) selection 
approach was used to arrive at a final logistic regression model with factors with a p < 0.05 
retained in the final model. The Hosmer-Lemeshow test was calculated to assess the 





4.3.1 Univariable analyses for determining risk factors for seropositivity 
in sheep and goats flocks 
 
The association between management and husbandry practices with seropositivity at the 
flock level are summarised in Table 4.2. Farmers who had introduced sheep into their flock 
in the 12 months preceding the survey were significantly more likely to have one or more 
seropositive (60%) animals in their flock (OR: 5.67, 95%CI 1.5 - 21.8; P value 0.013) than 
those who hadn’t introduced sheep (20.9%). Farmers who introduced goats into their flock 
in the 12 months preceding the survey were also significantly more likely to have a flock 
containing seropositive (46.2%) animals (OR 3.7, 95%CI 1.1 - 12.5; P value 0.026) than 
those who hadn’t introduced new goats (18.7%) (Table 4.2).  
 
Farmers who had vaccinated their sheep against brucellosis in the 12 months preceding the 
survey were significantly less likely to have seropositive flocks (OR: 0.14, 95%CI 0.02 - 
0.79; P value 0.028) than farmers who did not vaccinate their sheep. Similarly farmers who 
vaccinated their goats against brucellosis in the 12 months preceding the survey also were 
significantly less likely to have seropositive flocks (OR: 0.19, 95%CI 0.05 - 0.79; P value 









Odds ratio  
(95%CI) 
P value 
Grazed with other 
flocks 
Yes 2 (40.0) 5 2.57 (0.41 - 16.1) 
0.287* 
No 29 (20.6) 141 1.0 
History of abortion in 
sheep (last 12 months) 
Yes 27 (27.6) 98 4.2 (0.92 - 19.0) 
0.061* 
No 2 (8.3) 24 1.0 
History of abortion in 
goats (last 12 months) 
Yes 10 (23.8) 42 1.05 (0.41 - 2.7) 
0.919 
No 14 (23.0) 61 1.0 
Aborted foetuses / 
Threw away 
Yes 29 (26.4) 109 - 
0.335* 
No 0 (0.0) 6 - 
Aborted foetuses / 
Gave to dog 
Yes 23 (25.3) 91 1.01 (0.36 - 2.9) 
0.978 
No 6 (25.0) 24 1.0 
Aborted foetuses / 
Burnt 
Yes 0 (0.0) 0 - 
- 
No 29 (25.0) 116 - 
Purchased sheep in the 
preceding 12 months 
Yes 6 (60.0) 10 5.67 (1.5 - 21.8) 
0.013* 
No 23 (20.9) 110 1.0 
Purchased goats in the 
preceding 12 months 
Yes 6 (46.2) 13 3.7 (1.1 - 12.5) 
0.026 




Yes 9 (24.3) 37 1.27 (0.52 - 3.1) 
0.595 
No 22 (20.2) 109 1.0 
Spring 
Yes 19 (27.9) 68 2.13 (0.95 - 4.8) 
0.064 
No 12 (15.4) 78 1.0 
Well 
Yes 23 (19.3) 119 0.57 (0.22 - 1.5) 
0.237 
No 8 (29.6) 27 1.0 
Sheep vaccinated 
against brucellosis 
Yes 25 (21.6) 116 0.14 (0.02 - 0.79) 
0.028* 
No 4 (66.7) 6 1.0 
Goats vaccinated 
against brucellosis 
Yes 18 (19.4) 93 0.19 (0.05 - 0.79) 
0.026* 
No 5 (55.6) 9 1.0 
Yes = present, No = absent 
* Results from a Fisher’s exact test 




4.3.2 Multivariable analysis to identify factors influencing the 
seroprevalence of brucellosis in sheep and goats flocks 
 
Of the 13 variables analysed in the initial univariable analyses (Table 4.2), abortion history 
in sheep, introduced (purchased) new sheep, introduced (purchased) new goats, water 
sourced from a spring, water sourced from a well, sheep vaccinated against brucellosis and 
goats vaccinated against brucellosis had p values ≤ 0.25 and were offered to the initial 
multivariable logistic regression model.  
 
In the final model farmers who introduced (purchased) new sheep in the 12 months preceding 
the survey (OR: 4.24, 95%CI 1.0 - 17.3) and introduced (purchased) new goats in the 12 
months preceding the survey (OR: 15.2, 95%CI 3.0 - 76.36) were significantly more likely 
to have seropositive flocks (Table 4.3). In contrast, flocks that used water sourced from a 
well (OR: 0.27, 95%CI 0.09 - 0.84) and had goats vaccinated against brucellosis in the 12 
month period preceding the survey (OR: 0.31, 95%CI 0.12 - 0.75) were significantly less 
likely to have seropositive flocks (Table 4.3). The Hosmer-Lemeshow Test (P value 0.67) 




Table 4.3: Multivariable analysis to identify factors influencing the brucellosis flock status 
in sheep and goats in the Kurdistan Region, Iraq 
Variables β S.E. P value Odds ratios (95%CI) 
Purchased sheep in the 12 
months preceding the survey 
1.45 0.72 0.044 4.24 (1.0 - 17.3) 
Purchased goats in the 12 
months preceding the survey 
2.72 0.83 0.001 15.20 (3.0 - 76.36) 
Well water used for livestock - 1.32 0.58 0.023 0.27 (0.09 - 0.84) 
Goats vaccinated against 
brucellosis   
- 1.19 0.46 0.010 0.31 (0.12 - 0.75) 





A range of environmental, management, husbandry, host and agent factors can be directly or 
indirectly associated with the seroprevalence, transmission and distribution of brucellosis 
(Al-Majali et al. 2009, McDermott and Arimi 2002). In this study a questionnaire was 
administered to 146 owners of the 166 sampled flocks to identify putative risk factors for 
seropositivity to brucellosis in sheep and goat flocks located in the Kurdistan Region of Iraq. 
The risk factors detected in this study are closely related with a traditional management 




The final logistic regression model highlighted that flocks which introduced sheep (OR = 
4.2, 95%CI 1.0 - 17.3) or goats (OR = 15.2, 95%CI 3.0 - 76.4) in the 12 month period 
preceding the survey were more likely to be seropositive. Similar findings were reported in 
Oman (Al-Rawahi 2015) where a significantly higher seroprevalence was detected in 
imported sheep (0.6%) compared with local sheep (0.1%). Kabagambe (2001) highlighted 
that the movement of animals between flocks increased the risk of disease transmission and 
Crawford et al. (1990) reported that purchasing of infected replacement animals was the most 
important factor responsible for introducing brucellosis into previously free flocks. Boukary 
et al. (2013) also reported that mixing of newly arrived animals into a herd was highly 
correlated with brucellosis seropositivity. It is critical that introduced animals originate from 
a known diseases-free flock and it is also recommended these animals have a one-month 
period of quarantine on-farm of at prior to mixing with existing livestock to minimise the 
introduction of false negative animals (Mee et al. 2012) and to maintain a Brucella-free flock. 
The pens for quarantine need to be cleaned and disinfected regularly to prevent the potential 
exposure of existing livestock to pathogens carried by the newly acquired livestock 
(Villarroel et al. 2007). Also using birthing pens and regular cleaning of these has been shown 
to significantly reduced the odds of infection (Musallam et al. 2015). Purchasing animals 
from sale yards/auctions or livestock traders/dealers is of particular danger for the 
introduction of disease due to the uncertain origin of the animals or the potential for the 




In the current study, farmers who had vaccinated their goats in the preceding 12 months (OR: 
0.31, 95%CI 0.12 - 0.75) were less likely to have a seropositive flock than those who had not 
vaccinated their goat flock. Ganter (2015) also highlighted the role of vaccination in 
preventing brucellosis in sheep and goats and recommended that vaccination should be the 
main tool for disease control, particularly in low-income countries where the disease is often 
endemic. As outlined in Chapter Two a range of vaccines have been used to protect animals 
and flocks against brucellosis, with Rev-1 being the most effective one used in small 
ruminants (Blasco 2011). 
 
In the current study, farmers who used water sourced from wells were also less likely to have 
seropositive flocks (OR: 0.27, 95%CI 0.09 - 0.84). This is likely associated with the private 
ownership of wells, hence sheep and goats from these owner’s flocks are less likely to mix 
with other flocks for watering. The increased risk from contact with other flocks has been 
highlighted as a reason for disease transmission by others (Godfroid et al. 2011), as well as 
the potential for environmental contamination (Newell et al. 2010). Although direct contact 
with infectious material has been identified as a key feature for the horizontal transmission 
of Brucella spp. (Abubakar et al. 2012), and in the current study flocks which grazed with 
other flocks were more likely to be seropositive, this difference was not significant. Extensive 
grazing not only increases the likelihood of contact with potentially infected flocks, but also 
increases the opportunity for direct or indirect contact with wildlife, which can also be a 
reservoir for Brucella spp. (Muma et al. 2006). In Kurdistan sheep and goats can share 
grazing land with potentially infected wildlife, such as wild boars (Sus scrofa) Personal 
Communication Dr Ali, Kirkuk Hospital, and the role of these in transmission of infection to 
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domesticated animals cannot be discounted, although in Iraq it is likely that contact with 
other infected flocks is a more important factor in disease spread.  
 
In this study sheep flocks with a history of abortion were more likely to be seropositive (OR: 
4.2, 95%CI 0.92 - 19.0) than those without a history of abortion. This is not surprising as the 
characteristic clinical sign of brucellosis, particularly in small ruminants, is abortion (Blasco 
2011). Renukaradhya (2002) similarly observed that flocks with a history of abortions had a 
higher seroprevalence of brucellosis. However, in the study reported by Al-Rawahi (2015) 
in Oman there was no association between a history of abortions in sheep and seropositivity. 
The differences in results between studies may be due to the sample size or the management 
of flocks where some flocks are more intensively managed and observed hence increasing 
the likelihood of detection of abortions, if present.  
 
Incorrect disposal by herders of materials from abortions and potentially contaminated after-
birth was also found in this study. This has the potential to result in environmental 
contamination of grazing pastures and watering points (Nakeel et al. 2016), resulting in the 
spread of infection. Assenga et al. (2016) reported that a history of retained foetal membranes 
in cattle herds or goat flocks was a significant risk factor for seropositivity. The aborted, 
foetal fluids and foetal membranes have been shown to contain a large number of Brucella 
organisms (Assenga et al. 2016, John et al. 2010) and their correct disposal through burning 
or deep burial is important to reduce environmental contamination and exposure of other 
animals to the bacteria (Deddefo et al. 2015). 
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In the current study the livestock owners/managers surveyed did not keep any systematic 
flock records or use an animal identification system and consequently no reliable data were 
available regarding the number of births, early mortalities, the birth of weak offspring or the 
number of abortions or still births occurring each year in the surveyed flocks. There is a need 
for the Iraqi and Kurdistan Regional Government, through the Ministry of Agriculture, to 
introduce a formal flock and animal identification system and to support the implementation 
of vaccination programs against infectious diseases, such as brucellosis and foot and mouth 
disease (FMD). As part of this extension an educational program should be implemented for 
livestock owners to improve flock biosecurity, which would also reduce the risk of 
introduction of other infectious diseases, such as FMD, and reduce the risk of human 
infection with Brucella spp. 
 
As brucellosis can have a significant impact on livestock production, understanding the 
economic impact of the disease in the Kurdistan Region is key to implementing cost-effective 
control practices, particularly given the potential for transmission of infection to humans. In 
the following chapter the results of an economic analysis are presented to enumerate the 





Benefit - cost analysis comparing two different vaccination 




Infection with Brucella spp. is responsible for significant economic losses to the small 
ruminant industry because of abortions, premature births, reduced milk production and 
decreased reproduction rate (Ganter 2015). Despite the implementation of control programs 
the prevalence of brucellosis is increasing in many developing countries due to the influences 
of various sanitary, socioeconomic and political factors (Ganter 2015, Seleem 2010). The 
difficulties in controlling and eradicating brucellosis are often related to animal husbandry 
and management practices adopted, such as the coexistence of several livestock species and 
extensive grazing (Godfroid et al. 2011). Successful elimination programs have always been 
long, costly and hard to carry through (Godfroid et al. 2011). 
 
In countries where brucellosis is endemic, such as Iraq, control of the disease is by a 
combination of mass vaccination and prevention of Brucella spp. entering farms through 
biosecurity. These control methods are considered to be the best methods, and frequently the 
only reasonable strategies, to apply in situations where the disease has a high prevalence and 
herds/flocks are managed extensively (Corbel et al. 2006).   
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The basis of any policy to control brucellosis is to limit the exposure of susceptible animals 
to Brucella organisms. The mitigation strategies adopted depend upon the prevalence of the 
disease, geographical considerations, resource availability (both human and financial) and 
the desire to either eradicate or control the disease (Banai 2002). Loss of production or 
productivity is the most significant direct economic impact of brucellosis on the livelihood 
of farmers (McDermott et al. 2013, McDermott and Arimi 2002). The disease may also affect 
the local or national economy when a serious outbreak happens through reducing the quantity 
of animal products, such as meat and milk, available for sale to the general public (Seleem 
2010). Substantial and on-going financial support from the government and active 
involvement of farmers are important for the success of a regional and national brucellosis 
control program (Corbel et al. 2006). Data on the economic losses from brucellosis and the 
cost of the control programs proposed are required before selecting and implementing control 
measures. This study was undertaken to estimate the economic value to the small ruminant 
industry arising from a mass vaccination programme against brucellosis in sheep and goats 
in the Kurdistan Region of Iraq and comparing it to the status quo, namely vaccinating only 
lambs and kids from 3 to 6 months of age. 
 
5.2 Materials and Methods  
 
In the economic analysis reported in this chapter a benefit - cost analysis was undertaken (the 
total amount lost per year and the average loss per adult female were also calculated) to 
compare a mass vaccination control program involving vaccination of both young and adult 
animals for 10 years, with the current vaccination program which involves vaccinating only 
lambs and kids from 3 to 6 months of age. Based on the results of the questionnaires 
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administered to farmers (Chapter 4), a total of 57,145 sheep and goats were owned by the 
146 surveyed farmers of which 53.3% (30,458) were adult females, 3.7% (2,115) were adult 
males and 43% (24,572) were lambs or kids under one year of age. Available statistics from 
the Ministry of Planning for 2010 indicated that the total number of sheep and goats in 
Kurdistan region and Kirkuk province was 4,497,906 head (3,246,115 sheep and 1,251,791 
goats) (KRG 2012). For the purpose of this study only losses in adult female small ruminants 
(sheep and goats) were included in the model to estimate the costs associated with 
brucellosis, as the majority of the economic impact of the disease results from abortions and 
reduction of milk production in these species (Seleem 2010). The planned new vaccination 
strategy was to vaccinate 100% of the animals (both entire males and females, young and 
adult animals). 
 
In this study, a discount rate of 4.0% was applied as the average discount rate in the Kurdistan 
Region in 2014 (KRG 2015). The most likely price of a lamb or kid was estimated at US$50 
(range 45 - 55) (data from questionnaire). The overall real prevalence of brucellosis in this 
study was 4.92% (95%CI 3.7 - 6.4%) among sheep and goats (test results from Chapter 3).  
 
The main economic impact of the disease in sheep and goats is associated with production 
losses arising from abortions and reduced milk production (McDermott et al. 2013) and these 
aspects were focused on in this study. Economic analyses of control options for zoonotic 
diseases are complex and require data which are currently lacking from Kurdistan and Iraq. 
Consequently for some parameters estimates from other countries, or opinions from the local 
veterinary services or other experts were used (Tables 5.1 and 5.3). The average abortion rate 
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attributable to brucellosis in infected pregnant sheep and goats was estimated at 30% (range 
19 - 36%) per year (assumption as there is really no good quality study that has calculated 
the risk of abortion due to brucellosis). 
 
The fertility rate in local goats in Iraq was assumed to be 75.74% (range 72.96 - 78.67%) per 
season (Raoof et al. 2016). According to Hermiz et al. (1998) the average milk production in 
local goats in Iraq is 98 kg (range 94.3 - 101.7 kg) spread over 173 days in each of the two 
lactation periods per year. It is assumed that aborted animals do not produce any milk. A 
current price of milk of US$ 1 per litre was used in this study (Table 5.1). Due to a lack of 
available data regarding the average fertility rate and milk production of local sheep in Iraq, 
the values from local goats in Iraq were used for both sheep and goats in this study.  
 
The direct costs for the new vaccination program (vaccine and its administration) included 
the salaries of the vaccination team members, transport costs of the vaccine, transportation 
for the vaccination team members and expenses for holding the sub-district farmers’ 
meetings. To implement a vaccination program in Kurdistan, it is proposed that 90 teams are 
needed, where each team is comprised of one veterinarian, two veterinary nurses and one 
driver. These teams work for the Veterinary Medical Centres in the districts and sub-districts 
for a period of 30 days each year to ensure 100% (all adult and young animals) vaccination 




Table 5.1: Economic parameters used in this study 
Description Most likely value 
(min, max) 
Reference/source 
Abortion rate per year 30% 
(19 - 36%) 
Assumption 
*Fertility rate per season 75.7% 
(73.0 - 78.7%) 
Raoof et al. (2016)  
Average milk production per 
adult female per year (kg) 
98 
(94.3 - 101.7) 
Hermiz et al. (1998)  
Lambing/kidding seasons per 
year 
2 Questionnaire data (Chapter 4) 
Average price of one lamb or kid 
/ USD 
$50 (45 - 55) Questionnaire data (Chapter 4) 
Average price of milk per kg $1USD Questionnaire data (Chapter 4) 
Discount rate  4% KRG (2015)  
Percentage of adult females 53.3% Questionnaire data (Chapter 4) 
Percentage of adult males 3.7% Questionnaire data (Chapter 4) 
Percentage of lambs/kids  43% Questionnaire data (Chapter 4) 
$ (United States dollar)  $1 = 1,190 IQD https://www.mataf.net/  
*Fertility rate per season for local goats in Iraq was used for all adult females (sheep & goats) 
 
The assumptions included in this modelling were:  
• Estimated $3,200 salary per team per month = 90 (teams) × 3,200 = $288,000.  
• Estimated $20 per day for general consumables (such as ice boxes and ice blocks for 
packaging vaccines, fuel, syringes, expenses for sub-district meetings and 
administration) per team = 20 × 30 × 90 = $54,000.  
• It was estimated that the Brucella vaccine would cost USD $0.10 per dose (Director 
of the Veterinary services) = 4,500,000 (doses) × $0.10 = $450,000.  
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The total costs of the mass vaccination control program in the first year = $288,000 (salary) 
+ $54,000 (consumables) + $450,000 (cost of vaccine) = $792,000. It was assumed that the 
costs of vaccine and general consumables will increase by 4% per year, however the salary 
was assumed to remain the same for the 10 year period because salaries rise very slowly, if 
at all, in Kurdistan. 
 
This study assessed the impact of brucellosis on abortions and milk production according to 
the formulas listed below. Data on the costs of treatment, number of cases of still births, 
orchitis, epididymitis and mastitis were not included as little data were available regarding 
these features of the disease in sheep or goats for Iraq and they are of less importance than 
abortions and reduced milk yield (Lopes et al. 2010, Seleem 2010). 
 
Economic losses = A + M 
 
Where: A is the cost of an abortion [A = number of positive females (sheep and goats) × 30% 
(abortion rate) × 75.74% (fertility rate) × 2 (lambing/kidding seasons per year) × $50 
(average price of one lamb or kid)]. 
M is the cost of the milk production loss [M = number of positive female (sheep and goats) 
× 30% (abortion rate) × 75.74% (fertility rate) × 98 kg/year (milk production per adult female 




Benefit-cost analysis is a method that is commonly used to determine whether the benefits 
arising from a control program exceed the costs of conducting that program. The median and 
its 95%CI for the Net Present Value (NPV), Benefit Cost Ratio (BCR), and Internal Rate 
Return (IRR) were calculated (Marsh 1999). A NPV value greater than zero means that the 
proposed program is economically profitable, as does a BCR greater than 1 (Marsh 1999). 
 
A sensitivity analysis was carried out to account for uncertainty in values for six input 
variables (abortion rate, fertility rate, lambing/kidding seasons per year, price of a lamb/kid, 
milk production per adult female per year and average price of milk per kg) in the mass 
vaccination control program to identify which input parameters had the greatest effect on the 
uncertainty of the NPV and BCR through examining the normalised regression coefficients. 
These variables were expressed as probability distribution functions using @Risk 7.5 student 
version (Palisade Decision Tools, Palisade Corporation). The model was run for 10,000 
iterations using the variables specified as @Risk functions, Pert (minimum, most likely and 
maximum) distributions (Table 5.2). The protection rate was estimated using a combination 
of the efficacy of the available vaccine and vaccine coverage. Scenarios of 60% (efficacy of 
vaccine: 75% and vaccination coverage: 80%), 71.25% (efficacy of vaccine: 75% and 
vaccination coverage: 95%) and 80.75% (efficacy of vaccine: 85% and vaccination coverage: 




Table 5.2: List of input variables used as @Risk functions 
Name  @ Risk function* 
Abortion rate per year (%) 19, 30, 36 
Fertility rate per year (%) 72.96, 75.74, 78.67 
Average milk production per adult female kg per year 94.3, 98, 101.7 
Average price (USD) of one lamb or kid $45, $50, $55 
Average price (USD) of milk per kg $0.9, $1, $1.1 
*Data used in the Pert distribution: minimum, most likely, maximum values 
 
It was assumed that, with the current vaccination programme (vaccinating young animals 
only), brucellosis would be at an endemic equilibrium, where the number of newly infected 
animals (sheep or goats) produced by one infectious animal (sheep or goat) during its 
infectious period would equal 1. In this context, the number of newly infected animals (sheep 
or goats) each year would be the same as the number of infected animals (sheep or goats) 
that died or were culled/sold (removed). The calculation of new cases was derived from the 
following  formula (Dohoo et al. 2003):  
Re = R0 × s 
Where: Re is the effective reproduction number, which is the average number of secondary 
cases that result from an infectious individual in a particular population. R0 is the basic 
reproduction number, which is the average number of secondary infections arising from one 
infectious animal in a totally susceptible population, and s is the proportion of susceptible 




Table 5.3: Demographic parameters used to simulate brucellosis transmission dynamics and 
mass vaccination control program strategy in the Kurdistan Region 
Parameter Description  Value Reference/source 
RP 
Real prevalence  
RP =(TP + Sp -1)÷(Se + Sp -1)  
5.8% 
(4.5 - 7.4%) 
Chapter Three 
TP Test prevalence 
4.9% 
(3.6 - 6.3) 
Chapter Three 
s 
Proportion of susceptible 
animals 
0.5008 Calculation (s = 1-RP-pr) 
pr 
Proportion of protected 
animals 
0.45 Calculation (pr=vc*ve) 
vc Vaccination coverage baseline  60% 
Directorate of Dohuk 
Veterinary 
ve Vaccine efficacy baseline 75% El Idrissi et al. (2001) 
N 
Number of adult females 
(sheep and goats) 
2,397,383 
Total number of animals × 
percentage of adult females 
Ss Number of susceptible females 1,200,610 
Adult females - infected 
adult females  - protected 
females 
i Number of infected females 117,951 
Adult females × Real 
prevalence 
Re Effective reproduction number 1.0 
Assumption of endemic 
equilibrium 
R0  
Basic reproduction number  
R0 = Re/s 
1.9968 Dohoo et al. (2003)  
D Duration of infection 5 years 1/u 
u 
Replacement sheep per year / 
Cull rate 
20% 










5.3 Results   
 
Based on the data available, the total production losses due brucellosis in sheep and goats in 
2015 (year 1 or baseline) in the Kurdistan Region was estimated to be $6.14 million (95%CI 
$4.48 - $7.96 million) ($2.56 per adult female) with slightly more losses from abortions than 
reduced milk production (Table 5.4). By adopting a mass vaccination control program for 10 
years the annual production losses in sheep and goats due to brucellosis were estimated to 
decrease to $1.83 million (95%CI $1.33 - $2.39 million) ($0.76 per adult female) for losses 
arising from abortions and decreased milk production only (if the total number of adult 
females remained the same) (Table 5.4). 
 
Table 5.4: Losses (USD) due to brucellosis in baseline and during mass vaccination program  
Number of 
affected females 




Baseline 140,407 $3,102,727 $3,040,672 $6,143,399 
Year 2 127,770 $2,823,481 $2,767,012 $5,590,493 
Year 3 112,520 $2,486,485 $2,436,755 $4,923,240 
Year 4 98,033 $2,166,334 $2,123,008 $4,289,342 
Year 5 85,126 $1,881,118 $1,843,495 $3,724,613 
Year 6 73,851 $1,631,962 $1,599,323 $3,231,285 
Year 7 64,022 $1,414,773 $1,386,478 $2,801,251 
Year 8 55,530 $1,227,101 $1,202,559 $2,429,661 
Year 9 48,178 $1,064,642 $1,043,349 $2,107,991 





5.3.1 Benefit - Cost Analysis 
 
The results of the benefit - cost analysis are presented in Tables 5.5 and 5.6 and Figure 5.1. 
Benefits only included the reduced number of abortions and reduced milk loss in sheep and 
goats due to the control of brucellosis. For the mass vaccination control program compared 
to continuing the previous control measure using a 4% discount rate, the median NPV was 
US$11.22 million (95%CI 6.31 - 16.63 million) and the median BCR was 2.56 (95%CI 1.88 
- 3.31). The median cost of the mass vaccination program over the ten-year period was 
estimated at US$7.18 million (95%CI 7.11 - 7.25 million) and the total median benefit in 




Table 5.5: Summary of the results of the cost-benefit analysis comparing a mass vaccination control program with continuation 






Years Benefits (US$) Costs (US$) 
Future Value 
(US$) 
PV of Benefits 
(US$) 
PV of Costs 
(US$) 
NPV (US$) 
1 $0.00 $792,000.00 -$792,000.00 $0.00 $761,538.46 -$761,538.46 
2 $552,905.89 $812,160.00 -$259,254.11 $511,192.58 $750,887.57 -$239,695.00 
3 $1,220,158.31 $833,126.40 $387,031.91 $1,084,716.29 $740,646.34 $344,069.96 
4 $1,854,056.89 $854,931.46 $999,125.44 $1,584,855.60 $730,798.99 $854,056.61 
5 $2,418,785.44 $877,608.71 $1,541,176.73 $1,988,065.32 $721,330.39 $1,266,734.93 
6 $2,912,113.47 $901,193.06 $2,010,920.41 $2,301,485.58 $712,225.97 $1,589,259.61 
7 $3,342,147.80 $925,720.79 $2,416,427.01 $2,539,757.65 $703,471.71 $1,836,285.93 
8 $3,713,737.94 $951,229.62 $2,762,508.33 $2,713,591.94 $695,054.16 $2,018,537.78 
9 $4,035,407.97 $977,758.80 $3,057,649.17 $2,835,224.11 $686,960.36 $2,148,263.75 
10 $4,314,100.87 $1,005,349.15 $3,308,751.72 $2,914,451.97 $679,177.87 $2,235,274.11 
Total $24,363,414.59 $8,931,077.99 $15,432,336.60 $18,473,341.04 $7,182,091.83 $11,291,249.21 
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Table 5.6: Summary of Benefit - Cost analysis of a mass vaccination program conducted 
over a 10 year period to control brucellosis in sheep and goats in the Kurdistan Region  
Benefits (median and 95%CI) Costs (median and 95%CI) 
PV 
US$18,420,624 (13,426,580 - 
23,830,207) 
US$7,182,070 (7,113,637 - 
7,251,452) 
NPV US$11,224,173 (6,309,437 - 16,631,789)  
BCR 2.56 (1.88 - 3.31)  
IRR 67.9% (44.4 - 91.6%)  
  
 
The real prevalence of brucellosis in sheep and goats in Kurdistan region was predicted to 
decrease over 10 years from 5.81% (95%CI 4.5 - 7.4%) to 1.74% (95%CI 1.04 - 2.73%) due 
to the mass vaccination program. However, the real prevalence, if the current vaccination 
program was maintained, was predicted to stay at the same current level 5.81% (95%CI 4.5 









Figure 5.1: Predicted real prevalence of brucellosis in small ruminants over 10 years with a 





  5.3.2 Sensitivity analysis 
 
In the sensitivity analysis the abortion rate (Regression coefficient = 0.74) had the largest 
effect on the outcome. The prevalence of the disease (0.63) was the next important factor 
influencing the outcome. All other factors had minimal impact on the control program (low 
coefficients values ≤ 0.13) (Figure 5.2).  
 
 
Figure 5.2: Regression coefficients of the sensitivity analysis for the mass vaccination 
control program 
 
The results of the manual sensitivity analysis (Table 5.7) show that the NPV increased with 
increasing protection level. Increasing the protection level from 60% to 80.75% resulted in 
the NPV increasing from US$9,588,653 (95%CI: 5,218,434 - $14,183,401) to 





























Average price of one lamb or kids US$
Average price of milk per liter US$
Fertility rate






Table 5.7: Result of manual sensitivity analysis using different protection rates for the 
vaccinated animals 
IRR (%) BCR NPV (US$) Protection rate (%) 
63.99 
 (40.7 - 86.9) 
2.36  
(1.73 - 2.98) 
$9,588,653 
(5,218,434 - $14,183,401) 
60 
66.29 
(42.8 - 90.2) 
2.47 
(1.81 - 3.19) 
$10,534,449             
(5,827,738 - $15,729,215) 
71.25 
67.39 
(43.3 - 91.0) 
2.53 
(1.84 - 3.27) 
$10,984,762 




 5.4 Discussion 
 
The most effective control program for brucellosis can vary between countries and even 
regions within a country depending on the relevant risk factors for the disease and the 
management and husbandry practices adopted, including cultural practices (McDermott et al. 
2013). In the current chapter the results of an economic evaluation were presented to assess 
the net economic value of a mass vaccination control program spanning a 10-year period to 
control brucellosis in sheep and goats in Kurdistan. 
 
This study found that mass vaccination of animals resulted in a median NPV in the benefit-
cost analysis greater than zero and a median BCR ratio greater than one. These results indicate 
that the proposed vaccination program is financially viable. Benefits in this study only 
included the reduced number of abortions and reduced milk loss in sheep and goats due to 
the control of brucellosis. The NPV and BCR would have been even higher if data were 
available regarding the costs of treatment, number of cases of still births, orchitis, 
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epididymitis and mastitis as well as the benefits gain from reducing the incidence of infection 
in humans, however there are currently little data available regarding these features of the 
disease in sheep, goats or humans for Iraq. Although the proposed program was financially 
viable, implementing it would face challenges from instability of the veterinary infrastructure 
through conflicts internal and external to Iraq and uncertainty over vaccine availability. The 
results of this study are in agreement with the study conducted by Roth et al. (2003) who 
reported that if the overall costs of vaccinating livestock against brucellosis were allocated to 
all sectors in proportion to the benefits that would be gained, these interventions could prove 
profitable and cost effective for both the agricultural and human health sectors. 
 
In this study the proposed small ruminant brucellosis control program in the Kurdistan 
Region of Iraq was estimated to cost US$7.18 million ($7.11 - $7.25 million) over the 10-
year period, with the highest cost associated with the purchase of the vaccine and its delivery. 
Although vaccination does not eliminate infection, the model predicted a reduction in 
prevalence to 1.74% (95%CI 1.0 - 2.7) after ten years, at which time it might be possible to 
evaluate adopting eradication programs, such as test and slaughter programs (Corbel et al. 
2006). 
 
In the current study the sensitivity analysis demonstrated that, not surprisingly, improving 
the protection rate of the vaccine would result in a better economic performance for the 
vaccination control program. Similar results have been reported in other studies (Alves et al. 
2015, Roth et al. 2003). The sensitivity analysis indicated that the abortion rate had the largest 
effect on the outcome, followed by the prevalence of the disease, with all other factors having 
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minimal impact on the control program (low coefficients). The results of this study are in 
agreement with the study adopted by Blasco (2011) who suggested that abortion and 
infertility are the predominant clinical signs in small ruminants. Although there is a paucity 
of specific studies, brucellosis is recognised as a source of significant financial loss to 
livestock industries. 
 
It is critical to not only focus on vaccination, but concurrently establish a strong disease 
surveillance system involving the monitoring of all abortion cases by the provincial 
veterinary services to prevent reinfection or spread of disease. In addition, developing a 
strong quarantine system and preventing the illegal movement of animals from neighbouring 
countries, especially Syria and Iran, are important for the on-going control of brucellosis (as 
well as other diseases) in Kurdistan. The benefit of controlling brucellosis in small ruminants 
is not only important to reduce the economic impact of the disease in sheep and goats but 
also to reduce the infection in humans, as transmission of the disease between humans is rare 
and B. melitensis is a major cause of Brucella in humans (Blasco 2011). 
 
Brucellosis in animals mainly affects reproduction and fertility, and reduces the milk yield 
and the survival of new-borns lambs/kids, while mortality of adult animals is usually of minor 
importance. Reduced production or productivity is the most important direct economic 
impact of brucellosis on the profitability of rearing livestock, with abortions and reduction in 
milk yield the largest components of these losses (Ducrotoy et al. 2014). Small ruminants 
represent a major source of meat for Middle Eastern communities (Sherman 2011), therefore 
improving the livestock industries has been a major focus for many governments in the region 
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to improve both food safety and food security and the current study highlights the economic 
benefit in controlling brucellosis through mass vaccination. 
 
Critical to disease control are good management and husbandry measures, particularly 
associated with the introduction of animals, isolation/quarantine of animals which abort and 
the presence of wildlife which can act as potential reservoirs for the disease (Godfroid et al. 
2005). Therefore, control or elimination of these factors by improving flock biosecurity, 
disposing of aborted materials properly (for example burning and/or burying aborted 
materials) and isolating animals which abort from other animals in the flock, as well as 
purchasing new animals from confirmed brucellosis-free flocks will reduce the disease 
transmission in this region (Assenga et al. 2016). Reducing the prevalence of brucellosis in 
livestock, not only improves the productivity of livestock but also reduces the likelihood of 
disease in the human population as infection of humans nearly always is associated with 
contact with infected animals or their products (Godfroid et al. 2005). In the following 





A Retrospective Study of Human Brucellosis in Iraq 
6.1 Introduction  
 
Brucellosis in humans is widely distributed, with high endemic levels in the Middle East, the 
Mediterranean region and parts of Asia, Latin America and Africa (Shevtsov et al. 2015, 
Godfroid et al. 2011, Gwida et al. 2010, Moreno 2002). The most pathogenic and invasive 
species for humans in descending order are considered to be B. melitensis, B. abortus and B. 
suis (Acha and Szyfres 2003). Disease control can be challenging in many regions where the 
disease is endemic, as these locations/countries are typically characterised by large numbers 
of poor livestock keepers who adopt either extensive (often pastoral or nomadic) or intensive 
smallholder livestock systems (Ducrotoy et al. 2014). Animals and their products are the only 
significant sources of human brucellosis, and transmission predominantly occurs via 
consumption of unpasteurised dairy products or from direct contact with infectious material, 
particularly through occupational exposure in livestock keepers, abattoir workers and 
veterinarians (Corbel et al. 2006). Although attempts have been made to control brucellosis 
in both people and livestock in Iraq, the incidence of brucellosis in humans remains high 
(Pappas et al. 2006). It has even been questioned whether control of this disease can be 





Although the disease in animals has been eradicated from some countries where it was 
previously endemic (Pappas et al. 2006), new foci of brucellosis in humans have emerged, 
especially in central Asia. In addition, the disease is still present in both the USA (126 cases 
reported in humans in 2015) and in Europe (439 confirmed cases in humans were reported in 
2015) (ECDC 2016, CDC 2016). The annual incidence of brucellosis in people residing in 
endemic countries (such as the Mediterranean, Middle East, Latin America and parts of Asia) 
is reported to vary from < 0.01 to > 200 per 100,000 population (Dean et al. 2012a, Corbel 
1997). Although most humans are infected through occupational exposure to Brucella 
pathogens, with laboratory technicians, abattoir workers, veterinarians and farmers at a 
greater risk of infection than others (Galinska and Zagórski 2013, Dean et al. 2012a), 
infection through consumption of unpasteurised dairy products is also common (Kassiri et al. 
2013). In 2010 it was estimated that the global burden of foodborne diseases arising from 
brucellosis alone was 832,633 (95% uncertainty interval (UI) 337,929 - 19,560,440) (arising 
from eating contaminated products) (Kirk et al. 2015). 
 
Brucellosis in humans is usually a systemic infectious disease, resulting in various clinical 
manifestations (Corbel et al. 2006). The most common manifestations are fever, intermittent 
fever, malaise, excessive sweating, fatigue, anorexia, headache, myalgia, chills, weight loss, 
backache and arthralgia (Mantur 2007, Corbel et al. 2006). Brucellosis in humans may result 
in hepatomegaly, lymphadenopathy, osteomyelitis, meningitis, splenomegaly, endocarditis 
and epididymo-orchitis (Rahil et al. 2014). The case fatality rate of untreated brucellosis in 





The first case of human brucellosis in Iraq was confirmed in 1938 (Al Zahawi 1938). In the 
Kurdistan region there have, however, been very few studies investigating the incidence or 
prevalence of brucellosis in humans. In 1994, 15.2% of patients with fever presenting at 
public hospitals in Erbil Province were seropositive on the RBT (Shareef 2006). That same 
study indicated a higher level of seropositivity among rural residents and females than urban 
residents and males, respectively, with B. melitensis being the predominant species isolated 
(Shareef 2006). In Erbil Province, Rasul and Mansoor (2012) also found 10.7% of 2,085 
patients who presented to the Rizgary and Erbil Teaching Hospitals with fever and signs and 
symptoms similar to brucellosis, were seropositive on the RBT. 
 
The study reported in this chapter, which examined existing data sourced from the Ministry 
of Health, Kurdistan Regional Government of Iraq (KRG), was designed to investigate the 
historical distribution, incidence and cost of brucellosis in humans in Kurdistan. 
 
6.2 Materials and Methods 
6.2.1 Analysis of historical data on the incidence of brucellosis in humans 
in Iraq 
 
This study examined data from 1988 to 2014 sourced from the Ministry of Health, Iraqi 
Government and the Ministry of Health, KRG. The annual incidence of brucellosis per 
100,000 people from 2004 to 2008 in Kurdistan was compared with that for the rest of Iraq 
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and the incidence of human brucellosis (per 100,000 people) for the period 2009 to 2014 was 
also compared between the provinces of the Kurdistan region. 
 
Data on the number of cases of human brucellosis from 2009 to 2014 were collected from 
the Kirkuk Health Directorate and the Ministry of Health, KRG between March and May 
2015 and included the number of patients with brucellosis recorded by public hospitals in the 
different provinces of Kurdistan. In addition, data regarding the number of cases of human 
brucellosis in Iraq, excluding the Kurdistan region, which had been reviewed by other studies 
were included in this study to compare the local situation with that of the country. 
 
A survey of health sector experts was also conducted to estimate the total cost of brucellosis 
in humans. Thirty private health sector experts in Kirkuk province (10 from medical clinics, 
10 from diagnostic laboratories and 10 from pharmacies) were selected using a systematic 
random sample method to estimate the current costs arising from brucellosis. Human ethics 
approval was obtained from Murdoch University (2014/190) for this research. 
 
The average annual incidence of brucellosis in Iraq (including the Kurdistan region) and 
relative risks and their 95% confidence intervals were calculated to determine the association 
between the incidence in different areas and between periods. In addition, a Pearson's 
correlation coefficient and its P value were calculated to determine the correlation between 




6.2.2 Estimation of the financial burden of brucellosis to humans in Iraq 
 
The cost of brucellosis in humans includes both government health spending and costs 
incurred by private households containing affected individuals. However, because of the lack 
of data regarding the cost to the public health sector from human brucellosis in Iraq (including 
Kurdistan), this study used the current prices (based on a survey of health sector experts) in 
the private sector to estimate the total cost of brucellosis in humans. The costs included the 
consultation fee of a doctor, the number of doctor visits, the price of diagnostic tests and the 
cost of medicines recommended by the World Health Organisation (Ariza et al. 2007), as 
well as income lost in people suffering from brucellosis (Table 6.1). In this study it was 
assumed that the average monthly salary in Iraq was $663 ($22.10 per day) (Alghad-Press 
2017). For this study the total cost (TC) of brucellosis in humans in the Iraqi Kurdistan region 
per year was calculated as: 
 
TC = (A x B + C + D + E) x I 
 
Where A is the cost per outpatient visit (doctor’s fee); B is the number of outpatient visits per 
patient; C is the cost of the diagnostic tests; D is the costs of medical treatment per patient 
(medication costs were assessed on two weeks of streptomycin and six weeks of rifampicin 
and doxycycline therapy, intravenous fluid therapy, and anti-inflammatory and analgesic 
medicines); E is the income lost due to the illness per patient and I is the number of human 
cases in 2014. 
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Table 6.1: Parameters used to calculate the cost (US$#) per brucellosis patient in the private 
sector in the Iraqi Kurdistan region based on a survey of 30 health sector experts. 
Description Values (minimum, most likely, maximum) 
Doctor's fee per visit $8.40, $25.21, $42.02 
Cost of diagnosis (laboratory) $4.20, $21.01, $33.61 
Cost of treatment $18.70, $26.68, $32.77 
Days away from work 7, 10, 14  
Number of visits to the doctors 1, 2, 3 
Loss of income ($) due to the illness $154.70, $221.00, $309.40 
#US$ (United States of America dollar where US$1 = 1,190 IQD) (https://www.mataf.net/)  
 
According to the WHO (2018) the disability-adjusted life years (DALYs) for a disease or 
health condition are calculated as the sum of the years of life lost (YLL) due to premature 
mortality in the population and the years lost due to disability (YLD) for people living with 
the health condition or its consequences: 
DALY = YLL + YLD 
The YLL corresponds to the number of deaths multiplied by the standard life expectancy at 
the age at which death occurs and the basic formula for YLL is: 
YLL = N × L 
Where: N = number of deaths, L = standard life expectancy at age of death in years. 
To estimate YLD for a specific disease in a particular time period, the number of incident 
cases in that period is multiplied by the average duration of the disease and a weighting factor 
that reflects the severity of the disease on a scale from 0 (perfect health) to 1 (dead) (WHO 
2018). The basic formula for YLD is: 
YLD = I × DW × L  
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Where: I = number of incident cases, DW = disability weight, L = average duration of the 
case until remission or death (years). 
 
DALYs were estimated by assuming that brucellosis was associated with a disability weight 
of 0.191 (95%CI 0.172 - 0.211) (Dean et al. 2012b) and an average duration of 4.5 years 
(Singh et al. 2018). As no deaths were reported in two comprehensive surveys carried out on 
human brucellosis in India (Mantur et al. 2006, Mantur et al. 2004), this study assumed that 
the disease did not cause death and was only responsible for causing disability in infected 
persons. Therefore, DALYs were solely estimated from the years lost due to disability 
(YLD). 
 
To estimate the financial impact of brucellosis in humans in Kurdistan a model was 
developed using probability distribution functions for the input parameters (Table 6.1) in 
@Risk 7.5 student version (Palisade Decision Tools, Palisade Corporation) and run for 
10,000 iterations. A sensitivity analysis (assessed through examination of the calculated 
regression coefficients) was performed to account for uncertainty in values, and to determine 
the economic impact of brucellosis in humans as well as the impact of the number of 
incidence cases on DALYs occurring due to brucellosis in humans in the Kurdistan region in 
2014. This was achieved by using probability distributions for 6 input parameters for the cost 
of brucellosis in humans, and 3 input parameters for the number of DALYs. The Pert 
distribution was used for these parameters with data from the experts or literature used to 




6.3 Results  
6.3.1 Analysis of historical data on the incidence of brucellosis in humans 
in Iraq 
 
According to the official records from the Ministry of Health, Iraqi Government, the average 
annual incidence of brucellosis in Iraq, based on presenting clinical symptoms/signs and 
laboratory confirmation, for the period 1988 to 2002 was 41.88 cases per 100,000 people 
(Table 6.2). The annual incidence of brucellosis reported in humans for each year between 
1989 and 2002 were significantly higher than that reported for 1988. There were significant 
differences between years (overall P value < 0.0001) and the lowest annual incidence 
reported was 10.62 per 100,000 people in 1988 and the highest was 88.2 cases per 100,000 
people in 1995 (Table 6.2). 
 
In Table 6.3 the annual incidence of human brucellosis in the Kurdistan Region and other 
parts of Iraq for the period 2004 to 2008 are summarised. The average annual incidence over 
this five-year period was 54.11 per 100,000 people in Kurdistan which was significantly 
higher than the 17.82 per 100,000 people in the rest of Iraq (RR 3.0; 95%CI 1.76 - 5.11). The 
incidence was also significantly higher in the Kurdistan region compared to other areas of 
Iraq for every year data were available. The highest incidence in Kurdistan was 66.78 per 
100,000 people in 2007. In contrast the highest incidence in the rest of Iraq was 21.82 per 
100,000 people in 2005. The lowest incidence in Kurdistan was 37.85 per 100,000 people in 
2006, compared with 13.44 per 100,000 people in 2007 for other parts of Iraq. 
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Table 6.2: The annual incidence (based on clinical and laboratory diagnosis) of brucellosis 
in humans from 1988 to 2002 in Iraq  
Year*  Number of 




per 100,000 people 
Relative Risk  
(95%CI) 
1988 1,892 17,814,801 10.62 1.00 
1989 2,464 18,349,311 13.43 1.26 (1.19 - 1.34) 
1990 2,819 18,899,860 14.92 1.40 (1.32 - 1.49) 
1991 13,106 19,409,189 67.52 6.36 (6.06 - 6.67) 
1992 14,546 19,932,244 72.98 6.87 (6.55 - 7.21) 
1993 14,989 20,469,395 73.23 6.89 (6.57 - 7.23) 
1994 15,476 21,021,022 73.62 6.93 (6.61 - 7.27) 
1995 19,040 21,587,514 88.20 8.30 (7.92 - 8.71) 
1996 7,531 22,249,812 33.85 3.19 (3.03 - 3.35) 
1997 8,911 22,932,429 38.86 3.66 (3.48 - 3.84) 
1998 5,305 23,635,988 22.44 2.11 (2.01 - 2.23) 
1999 7,297 24,361,133 29.95 2.82 (2.68 - 2.97) 
2000 8,030 25,108,525 31.98 3.01 (2.86 - 3.17) 
2001 8,166 25,748,669 29.43 2.99 (2.84 - 3.14) 
2002 7,189 26,405,133 27.23 2.56 (2.44 - 2.70) 
* Salih (2010) who sourced the data from the Ministry of Health, Iraq 
 
Table 6.3: The annual incidence of brucellosis per 100,000 people from 2004 to 2008 in 
Kurdistan compared with the rest of Iraq (Source: Ministry of Health, Iraqi Government) 




2004 64.40 20.66 3.05 (1.86 - 4.99) 
2005 40.41 21.82 1.82 (1.08 - 3.06) 
2006 37.85 16.66 2.24 (1.26 - 3.96) 
2007 66.78 13.44 5.15 (2.86 - 9.33) 
2008 61.11 16.53 3.50 (2.10 - 6.14) 
Average    54.11 17.82 3.00 (1.76 - 5.11) 




The average annual incidence of brucellosis per 100,000 people for the study period 2009 to 
2014 in four different provinces of Kurdistan was 36.74. The highest average incidence was 
60.31 cases per 100,000 people in Sulaymani province and the lowest was 16.68 per 100,000 
people in Dohuk province (Table 6.4). 
 
Table 6.4: Annual incidence of human brucellosis (per 100,000 people) for the period 2009 
to 2014 in four provinces of Kurdistan#  
Years 
 
Provinces Average*   
Erbil Sulaymani Kirkuk Dohuk 
2009 50.52 60.34 50.46 27.51 49.26 
2010 40.96 74.80 44.18 35.72 51.29 
2011 16.18 66.24 41.83 20.38 38.56 
2012 12.67 54.78 20.31 11.13 29.37 
2013 4.87 53.10 26.86 2.61 24.55 
2014 28.68 52.57 20.98 2.71 29.77 
Average (2009 
to 2014) 




(1.31 - 1.85) 
3.71 
(3.18 - 4.34) 
2.18 
(1.84 - 2.58) 
1.00 - 
# Data from the Ministry of Health, KRG and Kirkuk Health Directorate 
*Average determined using raw data to account for population differences 
 
The annual incidence of human brucellosis in 2014 and the test seroprevalence in sheep and 
goats in different provinces in Kurdistan are summarised in Table 6.5. The highest incidence 
in humans in this year was 52.57 (95%CI 49.53 - 55.74) cases per 100,000 population in 
Sulaymani followed by 28.68 (95%CI 26.19 - 31.32) in Erbil province. Similarly, the highest 
test seroprevalence of brucellosis in both sheep and goats were in Sulaymani 5.67 (95%CI 
3.34 - 8.92) and Erbil 5.11 (95%CI 3.27 - 7.57) respectively. The Pearson's correlation 
coefficient calculated (0.8) and its P value (0.2004) indicated that there was a strong positive 
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correlation, but not significant, between the prevalence in sheep and goats and the incidence 
of brucellosis in humans in Kurdistan in the study year. 
 
Table 6.5: Incidence of human brucellosis (per 100,000 people) in 2014 compared with the 
seroprevalence to brucellosis in sheep and goats in four provinces of Kurdistan* 
Provinces  Annual incidence per 100,000 
people (95%CI) 
Test seroprevalence in sheep and 
goats % (95%CI) 
Erbil 28.68 (26.19 - 31.32) 5.11 (3.27 - 7.57) 
Sulaymani 52.57 (49.53 - 55.74) 5.67 (3.34 - 8.92) 
Kirkuk 20.98 (18.74 - 23.42) 3.5 (1.42 - 7.08) 
Dohuk 2.71 (1.73 - 3.61) 4.0 (1.1 - 9.93) 
Average 29.77 (28.47 - 31.12) 4.9 (3.67 - 6.39) 
* Data from Ministry of Health, KRG and Kirkuk Health Directorate 
 
6.3.2 Estimation of the financial burden of brucellosis to humans in Iraq 
 
The median cost per patient diagnosed with brucellosis was estimated to be $321.78 (95%CI 
$259.53 to $388.72). This equated to a median total cost of brucellosis for all affected humans 
in the Iraqi Kurdistan region in 2014 of $627,565.41 (95%CI $508,934.35 to $760,727.11). 
The median annual disability adjusted life years (DALYs) due to human brucellosis in the 
Iraqi Kurdistan region in 2014 was estimated to be 27.17 (95%CI 15.81 - 42.65) per 100,000 
people per year. As outlined in the materials and methods DALYs were estimated only using 




The sensitivity analyses for the cost estimation indicated that the loss of income due to illness 
(regression coefficient = 0.85) was the most sensitive variable for estimating the total cost of 
brucellosis followed by the doctor's fee per visit (regression coefficient = 0.37). All other 
factors had minimal impact on the cost of human brucellosis in Kurdistan (low coefficients) 
(Figure 6.1). The number of DALYs per 100,000 population was most sensitive to 
uncertainty in the duration of the disease (regression coefficient = 0.99). Other than for 
disability weight (regression coefficient = 0.15) all other factors had a coefficient estimate of 
less than 0.1 (Figure 6.2). 
 
 
Figure 6.1: Correlation coefficients of the sensitivity analysis for the effect of input 










































Figure 6.2: Correlation coefficients of the sensitivity analysis for the effect of input 




In Iraq, brucellosis is a widespread disease of both humans and livestock, and is distributed 
throughout the country being present in all provinces, including the Iraqi Kurdistan Region 
(Tables 6.2, 6.3, 6.4, 3.2 and 3.4). The geographical location of Iraq and the Kurdistan 
Region, where long porous borders are shared with Syria, Iran and Turkey, significant 
conflicts and wars over the past forty years, the uncontrolled illegal movement of animals 
from Syria and Iran to Iraq generally and the Kurdistan Region specifically and insufficient 
preventive and control programs have all contributed to the increased risk and spread of 
brucellosis within the region (Jaff 2016). The incidence of brucellosis in humans can vary 
widely, not only between countries but also within countries. This suggests that occupational, 
demographic and socioeconomic factors play a significant role in infection (Dean et al. 



































when developing control programs for the disease and prioritizing allocation of scarce 
resources. 
 
The current study presented data on brucellosis in humans sourced from the Ministry of 
Health, Iraqi Government for the period from 1988 to 2008. The average annual incidence in 
Iraq was 41.88 per 100,000 people with the highest incidence of 88.2 cases per 100,000 
people in 1995 which was significantly higher than that reported in 1988 (8.30; 95%CI 7.92 
- 8.71). The data from the Ministry of Health indicates that the average annual incidence of 
brucellosis in humans from 2004 to 2008 was on average 3 times (RR 3.0; 95%CI 1.76 - 
5.11) higher in the Kurdistan Region than in the middle and southern regions of Iraq. This 
may be due to a real difference or potentially underreporting due to a weak public health 
system in the middle and southern regions of Iraq because of the war in 2003 and the 
subsequent civil war. These hostile activities may have led patients to prefer treatment at 
private clinics rather than public hospitals. Unfortunately only official records for analysis 
were available from the public health service and consequently the estimated incidence is 
likely to be an underestimate of the true situation in Kurdistan and Iraq. Such information is 
important to be able to allocate sufficient resources to control brucellosis in humans, and 
future access to data from private health services would help address this issue.   
 
In the present study the highest average annual incidence of brucellosis in humans in the 
provinces of Kurdistan for the period 2009 to 2014 was in Sulaymani Province (60.03 per 
100,000 people). This was not unexpected as the highest seroprevalence of sheep and goats 
reported in Chapter 3 of this study was also in this province and consequently the risk of 
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transmission would be expected to be higher here than in other provinces due to the 
association of contact with infected animals or their products and disease in humans 
(Kozukeev et al. 2006). This highlights the importance of controlling the disease in livestock 
to control the disease in humans (Godfroid et al. 2011). 
 
To improve the understanding of the importance and impact of brucellosis in the Kurdistan 
region, an estimate of disease cost was calculated using data sourced from health sector 
experts in Iraq. The annual cost of brucellosis in humans in 2014 was estimated to be 
$627,565.41 (95%CI $508,934.35 - $760,727.11). Not surprisingly the cost of disease was 
most sensitive to uncertainty in the loss of income due to the illness and the doctor's fee per 
visit. This highlights the difficulty in making informed disease impact measurements in the 
absence of empirical data on disease frequency. The current study estimated a DALY of 
27.17 (95%CI 15.81 - 42.65) per 100,000 persons per year. The results of this study are higher 
than the study conducted by Singh et al. (2018) who estimated the disease was responsible 
overall for 15 DALYs (95%CI 13 - 17) per 100,000 persons per year in India. In that study 
they assumed that the average duration of disease was six months, there were no mortalities 
due to the disease and a disability weight of 0.19. The differences in the calculated DALYs 
are likely to arise from differences in disease within the livestock population, cultural 
differences between the two populations, and different assumptions made for the average 
duration of disease in humans and sample size differences. 
 
Unfortunately there were no available data recorded to enable a comparison of the incidence 
of brucellosis in humans residing in urban regions from those originating from rural areas. 
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However several previous studies conducted in this region (Jaff 2016, Rasul and Mansoor 
2012, Shareef 2006), not surprisingly, have reported a higher incidence in humans from rural 
areas. This is likely to arise from the greater contact a rural population would have with 
animals and their products such as aborted placenta, which is recognised as a key risk factor 
for infection (Rasul and Mansoor 2012). Residents in rural areas are also more likely to be 
less literate and come from a lower socioeconomic background than urban residents which 
have been highlighted by Muhammad (2009) and Racloz et al. (2013) as risk factors for 
infection. Adoption of simple preventive measures, such as boiling milk prior to 
consumption, can have a significant impact on the exposure of people to the bacteria (Corbel 
et al. 2006). From the author's experience there also is a need to improve management 
practices by livestock owners as, anecdotally, some owners sell or slaughter diseased animals 
for human consumption, including animals which have aborted potentially from brucellosis.  
Prevention of brucellosis in humans depends on the eradication or control of the disease in 
animal hosts (Corbel et al. 2006). To reduce and control the incidence of disease it is very 
important to apply a One Health Program principle involving aspects targeting the three 
components of human, animal and environment, to achieve the most effective outcome. This 
can be attained by veterinarians, public health authorities, farmers and consumers working 
together to increase awareness and education about the disease - its causes, routes of 
transmission and methods to avoid exposure to the pathogen. Because the rural health 
infrastructure is underdeveloped in Kurdistan, as well as in the rest of Iraq, there are 
insufficient community health workers in the region to control brucellosis with the primary 
focus of workers being on other, more common and potentially more infectious diseases of 
humans (Jaff 2016). However brucellosis in humans can be a debilitating disease and 
awareness of it is important in its control (WHO 2006) and critical to controlling the disease 
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in humans is effective control and preventive programs in livestock, including vaccination 
programs (Zinsstag et al. 2007). 
 
The Middle East has traditionally been considered an endemic area for brucellosis with five 
of the ten countries with the highest incidence of brucellosis in humans in the world being 
located there (Pappas et al. 2006). This high incidence can be attributed to political instability 
and the loss of adequate animal and human health services as the region has been plagued by 
war, famine and poverty for many years. In addition, a predominantly rural population, which 
is centred on livestock, and the low general literacy level of the population resulting in a lack 
of adoption of public health interventions would also account for the high incidence of human 
brucellosis (Pappas and Memish 2007). 
 
In conclusion, this chapter focused on the epidemiology of human brucellosis in Iraq 
generally and the Kurdistan region specially, from 1988 to 2014. The findings indicated that 
there was a high positive, although not significant correlation (0.8) between brucellosis in 
humans and sheep and goats in four provinces in Kurdistan and the disease was responsible 
for a significant cost to the individual and general public. Therefore adopting a mass 
vaccination control program in livestock is not only important in the control of brucellosis in 








Brucella melitensis, the first species in the genus Brucella to be described by Bruce in 1887, 
causes abortions in pregnant animals and Malta fever in humans. Brucellosis is consistently 
ranked among the most economically important zoonoses globally. It is a ‘multiple burden’ 
disease with economic impacts attributable to disease in livestock, humans and wildlife 
(McDermott et al. 2013, Seleem 2010, Corbel et al. 2006). The epidemiology and economic 
impact of brucellosis varies between locations and livestock systems adopted. In the Iraqi 
Kurdistan Region little was known about the distribution and impact of brucellosis in small 
ruminants prior to the current study. The study reported in this thesis was designed to further 
our understanding of the epidemiology of brucellosis in sheep, goats and humans in Kurdistan 
and involved four main components: undertaking a cross-sectional seroprevalence survey of 
sheep and goats to determine the distribution of infection within the region; administering a 
questionnaire to the owners/managers of sampled livestock to identify risk factors for 
infection at the individual and flock level; evaluating the economic impact of the disease in 
sheep and goats and the benefit of implementing a vaccination control programme; 
performing a retrospective study examining existing historical data to determine the 
distribution and frequency of brucellosis in humans and to estimate the costs arising from the 






Brucellosis is included in the list of animal diseases requiring compulsory vaccination in Iraq 
and the Kurdistan region. The current vaccination program in the Kurdistan region involves 
vaccinating only lambs and kids from 3 to 6 months of age, and the annual report from Dohuk 
Veterinary Hospital in 2015 indicated that 60% of lambs and kids in Dohuk Province had 
been vaccinated. However, even with this level of coverage and government attention to 
brucellosis, the real prevalence in sheep and goats in 2015 was 5.8% (95%CI 4.5 - 7.4) 
(Chapter 3). Although this was lower than the 16.4% reported by Salih (2010) in sheep and 
goat flocks in Kirkuk province, the disease is still likely to be having an economic impact on 
productivity and the current level of vaccine coverage is unlikely to control an epidemic 
disease such as brucellosis. The differences between the results of these two surveys may 
have arisen from differences in: adoption of vaccination control programs across Iraq; 
management and husbandry practices between provinces; or sampling strategies. 
 
This study found that the test seroprevalence was similar among sheep and goats and between 
males and females in the sampled provinces. These similarities are expected due to the similar 
traditional husbandry practices for handling both species and the similar management 
systems adopted between the sampled provinces. These findings were in agreement with 
other studies in Sulaymani and Nineveh provinces (Jabary and Al-Samarraee 2015, Al-




7.3 Economic assessment 
 
Brucellosis in sheep and goats is considered to be one of the most economically important 
zoonotic diseases due to its direct and indirect impact on both livestock and humans (Seleem 
2010). Many countries have conducted economic impact evaluations on the benefit of 
controlling this disease (Santos et al. 2013); however it is difficult to accurately assess the 
economic losses arising from this disease in the Kurdistan region specifically, and in all of 
Iraq generally, due to a lack of available data. In this study the economic impact of the disease 
in sheep and goats was investigated focusing on abortions and reduced milk production to 
explore the determinants of successful and sustainable control strategies within Kurdistan. 
 
This study (Chapter 5) found that the proposed mass vaccination program of sheep and/or 
goats over a 10-year period was economically viable (NPV > 0 and BCR > 1). The NPV and 
BCR would have been even higher if data were available regarding the number of still births 
and cases of orchitis and epididymitis, and lengthened inter-lambing/kidding interval. The 
results of this study are in agreement with the study conducted by Roth et al. (2003) regarding 
a positive return from controlling brucellosis in livestock. The estimated cost in this study for 
the proposed small ruminant brucellosis control program in the Kurdistan Region of Iraq was 
US$7.18 million over the 10-year period. The sensitivity analysis in this study indicated that 
the abortion rate followed by the average price of one lamb or kid had the largest effects on 
the outcome, and the results agreed with the study undertaken by Seleem (2010) which 
reported that the most significant economic losses from brucellosis arise from abortions and 
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consequently the size of the reduction in the abortion rate would be expected to have a major 
impact on the economic benefit arising from disease control. 
 
The findings from the model used in Chapter 5 predicted that annual whole flock vaccination 
was a technically effective vaccination strategy and economically viable in small ruminants 
and the NPV and BCR increased with increasing protection level (vaccine coverage and 
efficacy of vaccine). However, this control is dependent upon supply of sufficient doses of 
vaccine to vaccinate approximately 4.5 million sheep and goats each year, which will require 
support from the national and provincial Governments. 
 
7.2 Risk factors for infection 
 
Identifying and understanding risk factors for a disease are critical for the implementation of 
effective disease control programs (Porphyre et al. 2010). In general, the risk factors for 
zoonotic disease transmission are well documented in many parts of the world (John et al. 
2010, Busch and Parker 1972). The challenge is to find mitigation strategies that are easy to 
implement and which simultaneously enable livestock owners to benefit from disease control, 
whilst ensuring the good health of farmers and their families along with workers in high risk 
occupations and consumers (Schelling et al. 2007). This study is believed to be the first study 





The final logistic regression model indicated that sheep and goats flocks which introduced 
new animals in the 12 month period preceding the survey (OR = 4.2, 95%CI 1.0 - 17.3; OR 
= 15.2, 95%CI 3.0 - 76.4, respectively) were more likely to be seropositive than those that 
didn’t. Similar findings have been reported in other areas such as Oman, Niger and Uganda 
(Al-Rawahi 2015, Boukary et al. 2013, Kabagambe 2001, Crawford et al. 1990). It is well 
known that introducing new animals to flocks/herds, increases the risk of introducing infected 
animals (Dalrymple 1993), particularly if they are purchased from livestock traders/dealers. 
Therefore, it is important that all animals are tested with a test or tests of high sensitivity prior 
to introduction, or introduced animals only originate from a known brucellosis-free flock. 
Furthermore movement of animals from infected flocks should be restricted to sites such as 
meat works and sale to other farms/flocks should ideally be prohibited. Furthermore 
improved hygiene, such as washing hands before smoking or eating, and wearing personal 
protective equipment, such as gloves, masks and protective eyewear, should be encouraged 
within all flocks but particularly infected flocks as part of an educational campaign within a 
control program (Musallam et al. 2015, Robinson 2003). The FAO, OIE and WHO have 
made specific biosecurity recommendations for reducing the spread of brucellosis within 
flocks and flocks and to humans in contact with infected flocks. These include isolating 
individual animals during parturition, appropriate disposal of waste products, disinfecting 
pens and enclosures, and wearing personal protective equipment that is changed between 
handling individual animals (Corbel et al. 2006). 
 
The logistic-regression analysis highlighted an association of the source of water with the 
presence of disease (farmers who sourced water from wells were significantly less likely to 
have seropositive flocks). Direct contact with infected animals and contact with a 
129 
 
contaminated environment are the main reasons for disease transmission between animal 
flocks/herds (Shehada and Abu Halaweh 2013, Al-Majali et al. 2009). Using water sourced 
from private wells would decrease the likelihood of mixing of flocks, as well as potentially 
decreasing the likelihood of contamination of the water. Privately owned water sources are 
not only important to decrease the likelihood of a flock acquiring brucellosis but also 
potentially have economic benefits for farmers by decreasing the presence of other diseases 
such as rabies and FMD by reducing potential contact with other animals, vectors and 
wildlife. In areas such as Iraq, where cattle, sheep and goats are often grazed together, disease 
transmission between livestock species is likely to be one of the key drivers of disease spread 
and attempts should be made to minimise these contacts between animals of different 
herds/flocks/disease statuses. 
 
This study found that the farmers who had vaccinated their goats (Rev-1) in the preceding 12 
months were significantly less likely to have a seropositive flock (OR: 0.31, 95%CI 0.12 - 
0.75). These findings concur with those obtained by Ganter (2015) who reported the role of 
vaccination in preventing brucellosis in sheep and goats. Accordingly, while vaccination 
should be the cornerstone of the control effort, it should be accompanied by measures to 
facilitate and promote the adoption of good hygiene and husbandry practices that minimise 
the risks of introduction and maintenance of Brucella spp. as well as the risk of human 
infection. However in the 2014 annual report from the Directorate of Dohuk Veterinary DDV 
(2015) it was documented that only 60% of the lambs and kids between the ages of 3 to 6 
months had been vaccinated. It is important that this percentage is increased to at least 80% 




7.4 Brucellosis in humans  
 
The results of the study on human brucellosis indicated that the median cost per patient 
diagnosed with brucellosis was estimated to be $321.78 (95%CI $259.53 - $388.72) with an 
annual estimated cost of brucellosis for humans in 2014 of $627,565.41 (95%CI $508,934.35 
- $760,727.11) (Chapter 6). Other studies have demonstrated that brucellosis can result in 
large economic losses which are borne primarily by people involved in the livestock 
industries, however they do also affect the general community (Singh et al. 2015, Santos et 
al. 2013). 
 
This study found that there was a high positive correlation (0.8) between brucellosis in 
humans and animals in the sampled provinces. Zhu (2013) also highlighted that brucellosis 
in humans is always associated with infected animals or products from those animals, and 
effective control of the disease in animals will not only reduce the incidence in livestock with 
benefits to the farming community, but will also result in a lower incidence in humans, 
benefiting the total community. The current study examined data on the number of cases of 
human brucellosis from Kirkuk Health Directorate and the Ministry of Health in KRG for the 
period from 2009 to 2014 and the results indicated that the highest average annual incidence 
of brucellosis in humans was in Sulaymani Province (60.0 per 100,000 people). This finding 
was expected as the highest seroprevalence in animals in this study (Chapter 3) was also in 
Sulaymani Province. Therefore, giving priority or commencing an expanded vaccination 
programme in this province (or other provinces in Iraq with a high prevalence) will benefit 
both animals and humans. 
131 
 
In the historical data examined for human brucellosis sourced from the Ministry of Health, 
Iraqi Government for the period from 1988 to 2002, there were significant differences 
between years with the highest incidence of 88.2 cases per 100,000 people observed in 1995. 
This finding is probably associated with the United Nations sanctions on Iraq resulting in 
insufficient medical support at this time. According to the data from the Ministry of Health, 
Iraqi Government for the period from 2004 to 2008, the average annual incidence of 
brucellosis in humans (RR 3.0; 95%CI 1.8 - 5.1) was significantly higher in the Kurdistan 
Region than in the rest of Iraq. This is likely to be influenced by the fact that official records 
were only available for the public health services, and as a result of the war in 2003 and the 
subsequent civil war the public health system in the middle and southern regions of Iraq were 
weak. Therefore, the estimated incidences of brucellosis in humans in all parts of Iraq are 
likely to be underestimates of the true situation. Further studies are needed to assess the true 
incidence (including data from public and the private health sectors) of human cases in Iraq. 
 
Human brucellosis incidence data were only available from officially recorded cases from 
the Ministry of Health in KRG and the Iraqi Government, which may not reflect the true 
incidence in Iraq. In Mongolia, Zolzaya et al. (2014) conducted a seroprevalence study in 
humans and when they compared their results to official data, they found that the level of 
under-reporting to be 15-fold. Another study conducted in Kyrgyzstan estimated the true 
incidence to be up to 5.6 times higher than that officially recorded (Bonfoh et al. 2012). 
Therefore, the estimated DALY and the annual cost of brucellosis in humans in Iraq most 




7.5 Limitations of the present study 
 
Although the epidemiological study reported in this thesis produced several important 
findings, there were limitations associated with the study. Restricting the ability to accurately 
measure the impact of brucellosis is the scarcity of data on the livestock productivity losses 
attributable to the disease. Consequently for some parameters estimates from other countries 
or expert opinions were used, these parameters may under or overestimate the local values. 
These estimates potentially could have impacted upon the economic evaluation of the disease 
and hence the benefits arising from controlling brucellosis (Chapter 5). Although the 
questionnaires used in the current study played an important role in the methodology of the 
epidemiological study and were used for: identification of the risk factors of the disease and 
the economic evaluation of the disease, several factors, such as the current government policy 
and reluctant interviewees, also could have impacted upon the results. For example, the 
authorities have a policy of supporting farmers by supplying animal feed at a discounted 
price. This may have resulted in farmers concealing the true number (overestimating) of 
livestock, which could potentially bias the results. With respect to the study on brucellosis in 
humans, a major limitation with using the retrospective data was a lack of data from private 
clinics and consequently the estimated incidence is likely to be an underestimate of the true 
situation in Kurdistan and Iraq. Future access to data from private health services would help 




Diagnosis of brucellosis is usually made by antigen detection or through serological assays, 
however no test is 100% accurate (sensitive or specific) (Nielsen and Yu 2010). In the current 
study two tests have been used. All samples were tested with the RBT as a screening test and 
only samples positive on the RBT, plus an equal number of negative samples from the same 
locations, were retested with an ELISA to confirm the animal’s positivity. For the RBT, the 
agglutination intensity is affected by many factors including the amount of antigen, the 
temperature at which the test is run, the duration between adding the antigen and reading 
(interpreting the result), the experience and visual acuity of the test interpreter and potential 
cross-reactions with LPS of other bacteria (Cho et al. 2010). Potential false positive results 
due to vaccination (Munoz et al. 2005) could also have impacted upon the results. Finally, 
isolating (culturing) and identifying the infecting Brucella species and biotype was not 




Control measures for diseases, including brucellosis, should be based on sound 
epidemiological reasoning and it is unlikely that one specific program is suitable for all 
regions or countries. To plan and implement a program, several considerations for each 
situation (country or region) have to be undertaken. Firstly it is important to specify whether 
the goal of the program is the control or eradication of the disease and this is influenced by 
the financial situation within the country and the impact of the disease. Secondly, it is critical 
to have accurate information about the factors associated with the disease (Al-Rawahi 2015). 
These factors include the location and environment where the disease is distributed, the 
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animal population and the management and husbandry practices adopted, the expected 
prevalence, the culture of the owners and their willingness to cooperate in a control program. 
Once the situation with respect to the disease is known, the country may go for a specific 
strategy or a combination of strategies to control the disease. Ideally, permanent identification 
of animals and screening of animals with a suitable test, such as the RBT and/or ELISA, is 
recommended before selecting a specific control program to implement (Chen et al. 2016, 
Senein and Abdelgadir 2012, Seleem 2010). 
 
Many countries free from Brucella have a strong quarantine and border control system, a 
policy of slaughtering all infected and in-contact susceptible animals, as well as imposing 
strict restrictions on the movement of animals and vehicles from and around potentially 
infected premises. After slaughter the carcasses are either burnt or buried on the infected 
premises, the buildings thoroughly washed and disinfected, movement restrictions applied 
and the affected farms quarantined. In situations where the prevalence is low, a test and 
slaughter program could be adopted using the simple, rapid and inexpensive RBT with the 
positive results confirmed by another more specific test, such as an ELISA. However, the 
same process may not be ideal in populations with a high prevalence or in a country with a 
low prevalence but with limited financial resources. Therefore, a confirmatory process using 
more accurate tests (multiple tests) and different controlling methods has been adopted in 




Although brucellosis is one of the most common zoonotic diseases (Seleem 2010), many 
people still lack an awareness of the disease. If farmers had a better awareness of the risks of 
infection and the impact of the disease on their livestock and families, they would be more 
likely to take measures both to reduce transmission of the disease in their livestock and to 
minimise cross-species transmission to themselves and their families. Epidemiological 
analysis of health, disease and disability in the populations of most developed countries 
confirms the role of social, economic and environmental factors in determining increased risk 
of disease and adverse outcomes from disease (Harris et al. 1999). In order to increase 
awareness and encourage the adoption of better healthy behaviours, the government should 
conduct annual public education programs on the disease in schools and communities in rural 
areas. Information should be provided on the clinical signs, transmission routes and 
preventive and control measures for the disease. The educational message may be provided 
through various routes including television, radio broadcasts, warning signs, posters and 
newspapers (Chen et al. 2016). 
 
A policy of test and slaughter of all infected and in-contact suspected infected animals cannot 
be adopted in Kurdistan at this stage because of the endemic nature of the disease and the 
lack of suitable compensation for farmers. Consequently vaccination is considered the best 
way to initially control the disease in the region as the vaccine, Rev-1, is efficacious in adults, 
as well as animals 3 to 6 months of age, and induces a high and durable immune response 
(Blasco 1997, Alton and Elberg 1967). Compulsory mass vaccination, free voluntary testing, 
development of farm and an individual animal identification system and control of the illegal 
movement of animals from neighbouring countries potentially would reduce brucellosis in 
both humans and livestock. Despite the limitations of this study, the results of this analysis 
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suggest that mass vaccination with Rev-1 reduced overall costs and is potentially effective in 
reducing sheep and goat, as well as human, brucellosis costs. A well-operating surveillance 
system that incorporates current data collected from the field is required to control brucellosis 
(Robinson 2003). The main purpose of a surveillance system is to determine the need for 
immediate or long-term action in response to diseases and to provide information to optimise 
the use of the available resources through data analysis, determination of priorities, design of 
alternative actions, and determination of their likely costs and benefits (Corbel et al. 2006). 
Finally, a stronger border control system is important to prevent illegal movement of animals 
to Iraq which may impact upon any brucellosis control program. Subsequently a policy of 
test and slaughter of all infected animals could then be adopted in Kurdistan. 
 
7.7 Future research 
 
In order to obtain a better understanding of the epidemiological patterns of the disease in 
animals (sheep, goats and cattle) and to determine if sheep and goats are a spill-over host or 
a true reservoir, isolation and identification of the infecting Brucella spp. from sheep, goats 
and cattle should be further explored in Iraq. Because Brucella survives intracellularly in 
lymph nodes and mammary glands of ruminants after abortion, samples for identification 
should be taken from the lymph nodes of infected animals or from aborted foetuses (OIE 
2009). This research could provide information regarding the species and type of Brucella 
that is circulating in animals within Kurdistan especially and Iraq generally. More 
importantly, research could help to identify the most effective vaccines, as not all vaccines 
have the same efficacy against the various Brucella spp. (Adone and Pasquali 2013). 
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Many studies on the economic costs of brucellosis and its control have been carried out in 
developed (high-income) countries (such as the USA), however there is little information 
from developing (low-income and middle-income) countries (McDermott et al. 2013) such 
as Iraq. Due to different feed, animal husbandry and management practices, animal species 
present and veterinary and medical capacities, the economic impact of brucellosis could vary 
between species, regions and countries (Godfroid et al. 2013, Corbel et al. 2006, McDermott 
and Arimi 2002). Therefore, it is important to conduct further economic research into the 
effect of the disease on livestock in Kurdistan and other parts of Iraq. The results of such 
studies (amount of milk production in local goats per year, abortion rate due to brucellosis in 
local goats, number of cases of still births due to brucellosis in sheep and local goats) would 
allow a more accurate evaluation of the economic impact of the disease to be determined. 
This would provide direction for design and implementation of more effective control 
measures of the disease in the long term. 
 
Brucellosis affects a variety of terrestrial animals and wildlife species (Seleem 2010, 
Godfroid 2002) and occasionally disease can spill-over from wildlife to livestock and vice-
versa (Godfroid 2002). In Kurdistan there are thousands of wild deer and it is possible that 
frequent contact between wildlife species and livestock, in particular sheep and goats, will 
increase the risks of infection in the livestock. Consequently wildlife control may be required 
when the prevalence in livestock is low. In addition, infected placental material on pastures 
can be dispersed by dogs and other carnivorous animals, such as foxes, potentially resulting 
in exposure of Brucella to other susceptible livestock (EC 2001). Therefore, correct disposal 
of placental material through burning or deep burial is important to reduce environmental 
contamination and exposure of other animals within the infected flock (Deddefo et al. 2015). 
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In order to understand if wildlife species have been infected, and if there is a spill-over of 
infection from domestic animals to wild species or vice-versa, multidisciplinary research is 
required to study both domestic and wildlife species. If local wildlife are infected, it would 
increase the risk of the transmission of Brucella to domestic livestock and contribute to the 
persistence of brucellosis within the region. However, controlling brucellosis in wildlife 
reservoirs is complicated and costly (Olsen 2010). Conversely wildlife species could be 
exposed to the bacteria shed by infected livestock, so implementing a control program in 
livestock could minimise transmission to wildlife species and prevent the establishment of a 




In conclusion, this study focused on expanding information on the epidemiology of 
brucellosis in sheep, goats and humans in the Kurdistan region. Based on the findings, it is 
recommended that in order to effectively control the disease resulting in improved income 
for local farmers and less disease in the human population, an integrated approach should be 
implemented including adopting risk-based control measures, mass vaccination and 
education. These control measures would result in significant benefits to the economy as well 
as to public health. The evidence gathered and results presented in the thesis highlight how 
epidemiological, economic, social and political factors can influence the impact of brucellosis 
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Province:                      District:                 Sub district:  
Village:                 Record number: 1         Date:  
1- How many animals are in your herd? (       ) 
2- Type and number of your animals? 
 Number of males Number of females 
Sheep ≤ 6 months   
Sheep > 6 months    
Goats ≤ 6 months   
Goats > 6 months    
Other animals  Yes No Type Number 
    
    
    
    
 
3- Are your sheep and goats grazed outside your farm?    
Yes (   )                 No (     )  
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4- Are your sheep and goats grazed together or do they graze separately? 
Together (    )                Separately (    ) 
5- Are your sheep and goats grazed with other flocks of sheep or goats? 
Yes (    )                 No (    )  
6- If Yes – Approximately how many flocks do your flock graze with? (      ) 
7- If Yes - How long does your flock graze with other flocks each day?     (         ). 
8- Approximately how long does your flock graze for, in total, each day?  (         ). 
9- Approximately how many lambs and kids have been produced over the last 12 
months? 
Sheep:  Male (      ) Female (       )  Unsure:   (     ). 
Goats:  Male (      ) Female (       ) Unsure:   (     ).  
10- Did you have any abortions in your sheep during the last 12 months?   
             No:  (      ) Not Sure: (   ) Yes: (    )If yes how many (    ).  
11- If you had abortions in your sheep approximately at what stage (month) did the 
abortions occur? (    ) month.  
12- Did you have any abortions in your goats during the last 12 months?   
             No:  (    ) Not Sure: (   ) Yes: (      ) If yes how many (        ).  
13- If you had abortions in your goats approximately at what stage (month) did the 
abortions occur? (      ) month.   
14- Did all the abortions result in the birth of dead foetuses or did some survive for a     
period of time? 
All died (      ) Some survived (      ) 
15- How did you dispose of the aborted foetuses? 
Burnt (    )  Gave to dogs (    )   Threw away (    ) Other please specify ( ).  
16- Have you sold any sheep from your flock during the last year? 
No (    ) Yes (    ) If yes, how many?  (     ).   
17- Have you sold any goats from your flock during the last year? 
No (   ) Yes (     ) If yes, how many?  (     ). 
18- Have you purchased any sheep for your flock during the last year? 
No (    ) Yes (   )   If yes, how many?  (     ).   
19- If yes where did they come from? 
Same village (        ) Different village same sub-district (            ) 
Different village different sub-district (     ) 
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Different village different district (       ). 
20- Have you purchased any goats for your flock during the last year? 
No (    ) Yes (     ) If yes, how many?  (         ).   
21- If yes where did they come from?  
Same village (        ) Different village same sub-district (            ) 
Different village different sub-district (        ) 
Different village different district (       ).  
22- Approximately how much did you spend on food last year for your sheep? (       ). 
23- Approximately how much did you spend on food last year for your goats?  (       ). 
24- Approximately how much did you spend on the treatment of sick sheep in the past 
year?           (       ). 
25- Approximately how much did you spend on the treatment of sick goats in the past 
year?           (      ) 
26- What was the main disease/condition you treated your sheep for? 
(                                             ). 
27- What was the main disease/condition you treated your goats for? 
(                                             ).   
28- What is the source of water for your sheep and goats? 
River (    )   Well (   )     Spring (     )    Other please specify (  ) 
29- Do your sheep and goats share these water sources with sheep and goats from other 
farms?  Yes (    )                 No (   ) Not sure (     )   
30- Do you use electricity on your farm? 
Yes (    ) No (     ) 
31- Approximately how much did you spend on electricity for your sheep over the last 6 
months?  ( ) Not sure (      )  
32- Approximately how much did you spend on electricity for your goats over the last 6 
months?  ( ) Not sure ( ) 
33- Are there any paid agricultural workers on your farm? 
No (    ) Yes (    ) If yes how many (      ) 
34- Approximately what is the annual cost of these workers? 
Cost (      ) Not sure ( ) 
35- Were your sheep vaccinated against brucellosis during the last year? 
No (      ) Not sure (   ) Yes (     ). 
If yes how many times was it vaccinated in the last 12 months? (      )   
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If yes – In what month were they last vaccinated? (          ).  
36- Were your goats vaccinated against brucellosis during the last year? 
No (      ) Not sure (   ) Yes (     ). 
If yes how many times was it vaccinated in the last 12 months? (      )   
If yes – In what month were they last vaccinated? (       ). 
37- What do you think have been the three most important health problems in your 
sheep over the last 12 months? (                                                                         ). 
38- What do you think have been the three most important health problems in your 
goats over the last 12 months? (                                                                         ).  
39- Do you know if your sheep are infected with Brucella? 
Yes (    ) No (     ) Don’t know (     ).  
40- If yes how do you know your sheep are infected?  (                                                                 
). 
41- Do you know if your goats are infected with Brucella?  
Yes (    ) No (      ) Don’t know (     ).  
42- If yes how do you know your goats are infected?  (                                                                 
). 
43- Has brucellosis ever been diagnosed in your sheep or goat flock? 
Yes (     ) No (     ) Not sure (     ).   
44- If yes how many sheep and goats were infected? 
Sheep:  (          )                Goats:   (          )      Don’t know (           ).  
45- How much did you spend over the past year on your sheep to treat them for 
brucellosis? (          ). 
46- How much did you spend over the past year on your goats to treat them for 
brucellosis? (         ). 
47- How much did you earn from milk, wool & hair sales in the last 12 months from 
your sheep and goats? 
Income (                ) Not sure (     ).     
 
Thank you for taking the time to answer these questions. The results from this 
survey will help further our understanding of brucellosis in sheep and goats in 
Kurdistan.  
 
 
